PU.1/Pip	B-protein
and	O
basic	B-protein
helix	I-protein
loop	I-protein
helix	I-protein
zipper	I-protein
transcription	I-protein
factors	I-protein
interact	O
with	O
binding	B-DNA
sites	I-DNA
in	O
the	O
CD20	B-DNA
promoter	I-DNA
to	O
help	O
confer	O
lineage-	O
and	O
stage-specific	O
expression	O
of	O
CD20	B-protein
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

CD20	B-protein
is	O
a	O
B-lineage-specific	B-DNA
gene	I-DNA
expressed	O
at	O
the	O
pre-B-cell	O
stage	O
of	O
B-cell	O
development	O
that	O
disappears	O
on	O
differentiation	O
to	O
plasma	B-cell_type
cells	I-cell_type
.	O

As	O
such	O
,	O
it	O
serves	O
as	O
an	O
excellent	O
paradigm	O
for	O
the	O
study	O
of	O
lineage	O
and	O
developmental	O
stage-specific	O
gene	O
expression	O
.	O

Using	O
in	O
vivo	O
footprinting	O
we	O
identified	O
two	O
sites	O
in	O
the	O
promoter	O
at	O
-45	B-DNA
and	I-DNA
-160	I-DNA
that	O
were	O
occupied	O
only	O
in	O
CD20	B-protein
+	O
B	O
cells	O
.	O

The	O
-45	B-DNA
site	I-DNA
is	O
an	O
E	B-DNA
box	I-DNA
that	O
binds	O
basic	B-protein
helix-loop-helix-zipper	I-protein
proteins	I-protein
whereas	O
the	O
-160	B-DNA
site	I-DNA
is	O
a	O
composite	B-DNA
PU.1	I-DNA
and	I-DNA
Pip	I-DNA
binding	I-DNA
site	I-DNA
.	O

Transfection	O
studies	O
with	O
reporter	B-DNA
constructs	I-DNA
and	O
various	O
expression	O
vectors	O
verified	O
the	O
importance	O
of	O
these	O
sites	O
.	O

The	O
composite	B-DNA
PU.1	I-DNA
and	I-DNA
Pip	I-DNA
site	I-DNA
likely	O
accounts	O
for	O
both	O
lineage	O
and	O
stage-specific	O
expression	O
of	O
CD20	B-protein
whereas	O
the	O
CD20	B-protein
E	I-protein
box	I-protein
binding	I-protein
proteins	I-protein
enhance	O
overall	O
promoter	O
activity	O
and	O
may	O
link	O
the	O
promoter	O
to	O
a	O
distant	B-DNA
enhancer	I-DNA
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

PU.1/Pip	NULL
and	NULL
Basic	NULL
Helix	NULL
Loop	NULL
Helix	NULL
Zipper	NULL
Transcription	NULL
Factors	NULL
Interact	NULL
With	NULL
Binding	NULL
Sites	NULL
in	NULL
the	NULL
CD20	NULL
Promoter	NULL
to	NULL
Help	NULL
Confer	NULL
Lineage-	NULL
and	NULL
Stage-Specific	NULL
Expression	NULL
of	NULL
CD20	NULL
in	NULL
B	NULL
Lymphocytes	NULL
By	NULL
Andreas	NULL
Himmelmann	NULL
,	NULL
Agostino	NULL
Riva	NULL
,	NULL
Gaye	NULL
Lynn	NULL
Wilson	NULL
,	NULL
Brian	NULL
P.	NULL
Lucas	NULL
,	NULL
Claire	NULL
Thevenin	NULL
,	NULL
and	NULL
John	NULL
H.	NULL
Kehrl	NULL
CD20	NULL
is	NULL
a	NULL
B-lineage-specific	NULL
gene	NULL
expressed	NULL
at	NULL
the	NULL
pre-B-cell	NULL
stage	NULL
of	NULL
B-cell	NULL
development	NULL
that	NULL
disappears	NULL
on	NULL
differentiation	NULL
to	NULL
plasma	NULL
cells	NULL
.	NULL

As	NULL
such	NULL
,	NULL
it	NULL
serves	NULL
as	NULL
an	NULL
excellent	NULL
paradigm	NULL
for	NULL
the	NULL
study	NULL
of	NULL
lineage	NULL
and	NULL
developmental	NULL
stage-specific	NULL
gene	NULL
expression	NULL
.	NULL

Using	NULL
in	NULL
vivo	NULL
footprinting	NULL
we	NULL
identified	NULL
two	NULL
sites	NULL
in	NULL
the	NULL
promoter	NULL
at	NULL
-45	NULL
and	NULL
-160	NULL
that	NULL
were	NULL
occupied	NULL
only	NULL
in	NULL
CD20*	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
-45	NULL
site	NULL
is	NULL
an	NULL
E	NULL
box	NULL
that	NULL
binds	NULL
basic	NULL
helix-loop-helix-zipper	NULL
proteins	NULL
whereas	NULL
the	NULL
-160	NULL
site	NULL
is	NULL
a	NULL
composite	NULL
PU.1	NULL
and	NULL
Pip	NULL
binding	NULL
site	NULL
.	NULL

Transfec-	NULL
B-LYMPHOCYTE	NULL
DEVELOPMENT	NULL
proceeds	NULL
through	NULL
discrete	NULL
stages	NULL
characterized	NULL
by	NULL
ordered	NULL
DNA	NULL
rearrangements	NULL
of	NULL
the	NULL
Ig	NULL
loci	NULL
that	NULL
lead	NULL
to	NULL
transcription	NULL
of	NULL
Ig	NULL
genes	NULL
and	NULL
expression	NULL
of	NULL
B-cell	NULL
antigen	NULL
receptors	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
different	NULL
stages	NULL
of	NULL
this	NULL
developmental	NULL
process	NULL
can	NULL
be	NULL
distinguished	NULL
by	NULL
the	NULL
expression	NULL
of	NULL
specific	NULL
cell	NULL
surface	NULL
markers	NULL
.	NULL

Studies	NULL
of	NULL
the	NULL
promoter	NULL
and	NULL
enhancer	NULL
regions	NULL
of	NULL
Ig	NULL
genes	NULL
as	NULL
well	NULL
as	NULL
the	NULL
analyses	NULL
of	NULL
the	NULL
promoter	NULL
regions	NULL
of	NULL
several	NULL
B-lineage	NULL
genes	NULL
have	NULL
offered	NULL
some	NULL
insights	NULL
into	NULL
the	NULL
general	NULL
mechanisms	NULL
of	NULL
lineage	NULL
specific	NULL
gene	NULL
expression	NULL
.	NULL
``	NULL

''	NULL
Such	NULL
gene	NULL
expression	NULL
often	NULL
depends	NULL
on	NULL
a	NULL
complex	NULL
interplay	NULL
between	NULL
cis-regulatory	NULL
elements	NULL
and	NULL
a	NULL
large	NULL
number	NULL
of	NULL
transcription	NULL
factors	NULL
,	NULL
some	NULL
that	NULL
are	NULL
ubiquitously	NULL
expressed	NULL
and	NULL
others	NULL
that	NULL
are	NULL
expressed	NULL
in	NULL
a	NULL
lineage-restricted	NULL
manner	NULL
.	NULL

*	NULL
``	NULL
Often	NULL
there	NULL
are	NULL
direct	NULL
physical	NULL
interactions	NULL
between	NULL
the	NULL
different	NULL
transcription	NULL
factors	NULL
resulting	NULL
in	NULL
a	NULL
cooperative	NULL
regulation	NULL
of	NULL
a	NULL
specific	NULL
gene	NULL
.	NULL
``	NULL

Although	NULL
gene	NULL
targeting	NULL
experiments	NULL
in	NULL
mice	NULL
have	NULL
determined	NULL
that	NULL
several	NULL
transcription	NULL
factors	NULL
including	NULL
BSAP	NULL
,	NULL
'	NULL
EBF	NULL
,	NULL
``	NULL
E2A	NULL
,	NULL
'	NULL
PU.1	NULL
,	NULL
``	NULL
Â°	NULL
and	NULL
are	NULL
essential	NULL
for	NULL
normal	NULL
B-cell	NULL
development	NULL
,	NULL
this	NULL
approach	NULL
has	NULL
been	NULL
less	NULL
useful	NULL
in	NULL
defining	NULL
the	NULL
roles	NULL
of	NULL
these	NULL
transcription	NULL
factors	NULL
in	NULL
stage-	NULL
and	NULL
lineage-specific	NULL
gene	NULL
expression	NULL
because	NULL
B-cell	NULL
development	NULL
in	NULL
these	NULL
mice	NULL
arrests	NULL
at	NULL
a	NULL
very	NULL
early	NULL
stage	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
B-cell	NULL
marker	NULL
CD20	NULL
does	NULL
not	NULL
normally	NULL
appear	NULL
until	NULL
the	NULL
pre-B-cell	NULL
stage	NULL
,	NULL
hence	NULL
all	NULL
these	NULL
mutant	NULL
mice	NULL
lack	NULL
CD20-positive	NULL
B	NULL
cells	NULL
and	NULL
the	NULL
potential	NULL
roles	NULL
of	NULL
these	NULL
transcription	NULL
factors	NULL
in	NULL
CD20	NULL
gene	NULL
expression	NULL
can	NULL
not	NULL
be	NULL
assessed	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
molecular	NULL
mechanisms	NULL
governing	NULL
the	NULL
stage	NULL
and	NULL
lineage-specific	NULL
expression	NULL
of	NULL
CD20	NULL
remain	NULL
largely	NULL
unknown	NULL
.	NULL

After	NULL
its	NULL
appearance	NULL
on	NULL
pre-B	NULL
cells	NULL
,	NULL
CD20	NULL
persists	NULL
until	NULL
B	NULL
cells	NULL
From	NULL
the	NULL
B	NULL
Cell	NULL
Molecular	NULL
Immunology	NULL
Section	NULL
,	NULL
Laboratory	NULL
of	NULL
Immunoregulation	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Dis-eases	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
.	NULL

Submitted	NULL
October	NULL
22	NULL
,	NULL
1996	NULL
;	NULL
accepted	NULL
July	NULL
7	NULL
,	NULL
1997	NULL
.	NULL

Supported	NULL
in	NULL
part	NULL
by	NULL
a	NULL
Swiss	NULL
National	NULL
Foundation	NULL
Grant	NULL
to	NULL
A.H	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
John	NULL
H.	NULL
Kehrl	NULL
,	NULL
MD	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Building	NULL
10	NULL
,	NULL
Room	NULL
11B-13	NULL
,	NULL
10	NULL
Center	NULL
Dr	NULL
MSC	NULL
1876	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892-1876	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

This	NULL
is	NULL
a	NULL
US	NULL
government	NULL
work	NULL
.	NULL

There	NULL
are	NULL
no	NULL
restrictions	NULL
on	NULL
its	NULL
use	NULL
.	NULL

0006-4971/97/9010-0024	NULL
$	NULL
0.00/0	NULL
3984	NULL
tion	NULL
studies	NULL
with	NULL
reporter	NULL
constructs	NULL
and	NULL
various	NULL
expression	NULL
vectors	NULL
verified	NULL
the	NULL
importance	NULL
of	NULL
these	NULL
sites	NULL
.	NULL

The	NULL
composite	NULL
PU.1	NULL
and	NULL
Pip	NULL
site	NULL
likely	NULL
accounts	NULL
for	NULL
both	NULL
lineage	NULL
and	NULL
stage-specific	NULL
expression	NULL
of	NULL
CD20	NULL
whereas	NULL
the	NULL
CD20	NULL
E	NULL
box	NULL
binding	NULL
proteins	NULL
enhance	NULL
overall	NULL
promoter	NULL
activity	NULL
and	NULL
may	NULL
link	NULL
the	NULL
promoter	NULL
to	NULL
a	NULL
distant	NULL
enhancer	NULL
.	NULL

This	NULL
is	NULL
a	NULL
US	NULL
government	NULL
work	NULL
.	NULL

There	NULL
are	NULL
no	NULL
restrictions	NULL
on	NULL
its	NULL
use	NULL
.	NULL

terminally	NULL
differentiate	NULL
into	NULL
plasma	NULL
cells	NULL
.	NULL

'*	NULL
``	NULL
Although	NULL
the	NULL
exact	NULL
function	NULL
of	NULL
CD20	NULL
remains	NULL
unknown	NULL
it	NULL
is	NULL
likely	NULL
important	NULL
in	NULL
B-cell	NULL
activation	NULL
and	NULL
it	NULL
may	NULL
function	NULL
as	NULL
a	NULL
calcium	NULL
channel	NULL
.	NULL
``	NULL

The	NULL
CD20	NULL
promoter	NULL
has	NULL
been	NULL
cloned	NULL
and	NULL
CD20	NULL
promoter	NULL
constructs	NULL
behave	NULL
in	NULL
a	NULL
B-cell-specific	NULL
manner	NULL
.	NULL
``	NULL

''	NULL
Deletion	NULL
analysis	NULL
with	NULL
subcloned	NULL
promoter	NULL
fragments	NULL
of	NULL
various	NULL
sizes	NULL
identified	NULL
a	NULL
positive	NULL
cis-acting	NULL
element	NULL
located	NULL
between	NULL
base	NULL
pairs	NULL
-186	NULL
and	NULL
-290	NULL
.	NULL

Analysis	NULL
of	NULL
this	NULL
interval	NULL
of	NULL
the	NULL
promoter	NULL
with	NULL
mobility	NULL
shift	NULL
assays	NULL
showed	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
diverged	NULL
octamer	NULL
binding	NULL
site	NULL
that	NULL
interacted	NULL
with	NULL
the	NULL
B-cell-specific	NULL
transcription	NULL
factor	NULL
Oct-2	NULL
as	NULL
well	NULL
as	NULL
the	NULL
ubiquitous	NULL
transcription	NULL
factor	NULL
Oct-1	NULL
.	NULL
'	NULL

''	NULL
However	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
this	NULL
cis-element	NULL
is	NULL
sufficient	NULL
to	NULL
account	NULL
for	NULL
the	NULL
lineage-	NULL
and	NULL
stage-specific	NULL
activity	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
the	NULL
diverged	NULL
octamer	NULL
site	NULL
showed	NULL
that	NULL
this	NULL
element	NULL
is	NULL
responsible	NULL
for	NULL
only	NULL
about	NULL
40	NULL
%	NULL
of	NULL
the	NULL
promoter	NULL
activity	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
targeted	NULL
deletion	NULL
of	NULL
Oct-2	NULL
in	NULL
the	NULL
mouse	NULL
showed	NULL
that	NULL
Oct-2	NULL
is	NULL
dispensable	NULL
for	NULL
early	NULL
B-cell	NULL
development	NULL
and	NULL
does	NULL
not	NULL
affect	NULL
expression	NULL
of	NULL
the	NULL
CD20	NULL
antigen	NULL
.	NULL
``	NULL

We	NULL
have	NULL
used	NULL
in	NULL
vivo	NULL
footprinting	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSA	NULL
)	NULL
,	NULL
and	NULL
transient	NULL
transfection	NULL
experiments	NULL
to	NULL
identify	NULL
two	NULL
important	NULL
cis-regulatory	NULL
elements	NULL
in	NULL
the	NULL
proximal	NULL
part	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

One	NULL
element	NULL
homologous	NULL
to	NULL
the	NULL
AB	NULL
element	NULL
of	NULL
the	NULL
A	NULL
light	NULL
chain	NULL
enhancers	NULL
is	NULL
a	NULL
composite	NULL
binding	NULL
site	NULL
for	NULL
a	NULL
B-cell-specific	NULL
complex	NULL
composed	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
PU.1	NULL
and	NULL
its	NULL
interaction	NULL
partner	NULL
Pip	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
E3	NULL
element	NULL
close	NULL
to	NULL
the	NULL
CD20	NULL
transcriptional	NULL
start	NULL
sites	NULL
interacts	NULL
with	NULL
members	NULL
of	NULL
the	NULL
basic	NULL
helix-loop-helix-zipper	NULL
(	NULL
bHLHZ	NULL
)	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
lines	NULL
and	NULL
culture	NULL
.	NULL

-	NULL
BJA-B	NULL
(	NULL
Epstein	NULL
Barr	NULL
virus	NULL
negative	NULL
B-cell	NULL
lymphoma	NULL
)	NULL
cell	NULL
line	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
E.	NULL
Oates	NULL
(	NULL
Uni-versity	NULL
of	NULL
Miami	NULL
,	NULL
Miami	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

The	NULL
pre-B-cell	NULL
lines	NULL
PB697	NULL
and	NULL
NALM-6	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
T.	NULL
Tedder	NULL
(	NULL
Duke	NULL
University	NULL
,	NULL
Durham	NULL
,	NULL
NC	NULL
)	NULL
.	NULL

The	NULL
mouse	NULL
fibroblast	NULL
cell	NULL
line	NULL
NIH3T3	NULL
,	NULL
the	NULL
human	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
RPMI	NULL
8226	NULL
and	NULL
U266	NULL
,	NULL
the	NULL
human	NULL
plasmacytoma	NULL
cell	NULL
line	NULL
HS-Sultan	NULL
,	NULL
the	NULL
human	NULL
cervical	NULL
carcinoma	NULL
cell	NULL
line	NULL
HeLa	NULL
,	NULL
and	NULL
the	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
were	NULL
all	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
to	NULL
15	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
,	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
the	NULL
HeLa	NULL
and	NULL
NIH3T3	NULL
cell	NULL
lines	NULL
,	NULL
which	NULL
were	NULL
grown	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
FCS	NULL
.	NULL

Blood	NULL
,	NULL
Vol	NULL
90	NULL
,	NULL
No	NULL
10	NULL
(	NULL
November	NULL
15	NULL
)	NULL
,	NULL
1997	NULL
:	NULL
pp	NULL
3984-3995	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

REGULATION	NULL
OF	NULL
CD20	NULL
PROMOTER	NULL
In	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
genomic	NULL
footprinting	NULL
.	NULL

|	NULL
For	NULL
in	NULL
vivo	NULL
dimethyl	NULL
sulfate	NULL
(	NULL
DMS	NULL
)	NULL
treatment	NULL
and	NULL
DNA	NULL
isolation	NULL
,	NULL
1	NULL
X	NULL
10Â°	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
and	NULL
resuspended	NULL
in	NULL
2	NULL
mL	NULL
medium	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

DMS	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cells	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.5	NULL
%	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
4	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
ice-cold	NULL
PBS	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
lysed	NULL
in	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
/Proteinase	NULL
K	NULL
solution	NULL
and	NULL
incubated	NULL
at	NULL
55Â°C	NULL
for	NULL
4	NULL
hours	NULL
.	NULL

DNA	NULL
was	NULL
purified	NULL
by	NULL
two	NULL
phenol	NULL
extractions	NULL
and	NULL
two	NULL
phenol/chloroform	NULL
extractions	NULL
followed	NULL
by	NULL
one	NULL
chloroform	NULL
extraction	NULL
and	NULL
ethanol	NULL
precipitation	NULL
.	NULL

For	NULL
in	NULL
vitro	NULL
DMS	NULL
modification	NULL
genomic	NULL
DNA	NULL
was	NULL
first	NULL
extracted	NULL
in	NULL
an	NULL
identical	NULL
fashion	NULL
after	NULL
overnight	NULL
lysis	NULL
in	NULL
SDS/Protein-ase	NULL
K	NULL
solution	NULL
.	NULL

Then	NULL
200	NULL
ug	NULL
of	NULL
genomic	NULL
DNA	NULL
were	NULL
incubated	NULL
in	NULL
200	NULL
uL	NULL
of	NULL
TE	NULL
(	NULL
10	NULL
mmol/L	NULL
Tris	NULL
CI	NULL
and	NULL
1	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
pH	NULL
8.0	NULL
)	NULL
with	NULL
DMS	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.5	NULL
%	NULL
for	NULL
90	NULL
seconds	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

After	NULL
addition	NULL
of	NULL
50	NULL
4L	NULL
DMS	NULL
stop	NULL
solution	NULL
the	NULL
DNA	NULL
was	NULL
precipitated	NULL
with	NULL
ethanol	NULL
.	NULL

Piperidine	NULL
treatment	NULL
of	NULL
in	NULL
vivo	NULL
or	NULL
in	NULL
vitro	NULL
methylated	NULL
DNA	NULL
was	NULL
carried	NULL
out	NULL
by	NULL
incubating	NULL
200	NULL
pg	NULL
of	NULL
methylated	NULL
DNA	NULL
in	NULL
200	NULL
gL	NULL
of	NULL
1	NULL
mol/L	NULL
piperidine	NULL
(	NULL
Sigma	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
at	NULL
90Â°C	NULL
for	NULL
30	NULL
minutes	NULL
.	NULL

The	NULL
piperidine	NULL
was	NULL
removed	NULL
by	NULL
three	NULL
rounds	NULL
of	NULL
evaporation	NULL
and	NULL
by	NULL
ethanol	NULL
precipitation	NULL
of	NULL
the	NULL
DNA	NULL
pellet	NULL
three	NULL
times	NULL
.	NULL

Ligation-mediated	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
LMPCR	NULL
)	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
.	NULL

'Â®	NULL
For	NULL
each	NULL
region	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
analyzed	NULL
a	NULL
set	NULL
of	NULL
nested	NULL
primers	NULL
with	NULL
increasing	NULL
melting	NULL
temperature	NULL
(	NULL
designated	NULL
primer	NULL
1	NULL
to	NULL
3	NULL
)	NULL
were	NULL
used	NULL
.	NULL

Briefly	NULL
,	NULL
for	NULL
first	NULL
strand	NULL
synthesis	NULL
a	NULL
mixture	NULL
containing	NULL
genomic	NULL
DNA	NULL
,	NULL
Vent	NULL
polymerase	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
and	NULL
primer	NULL
1	NULL
was	NULL
incubated	NULL
at	NULL
95Â°C	NULL
for	NULL
5	NULL
minutes	NULL
,	NULL
60Â°C	NULL
for	NULL
30	NULL
minutes	NULL
,	NULL
and	NULL
76Â°C	NULL
for	NULL
10	NULL
minutes	NULL
.	NULL

The	NULL
linker	NULL
ligation	NULL
was	NULL
performed	NULL
at	NULL
16Â°C	NULL
for	NULL
16	NULL
hours	NULL
followed	NULL
by	NULL
an	NULL
ethanol	NULL
precipitation	NULL
.	NULL

Subsequently	NULL
,	NULL
the	NULL
first	NULL
amplification	NULL
step	NULL
was	NULL
carried	NULL
out	NULL
using	NULL
primer	NULL
2	NULL
and	NULL
a	NULL
linker	NULL
specific	NULL
primer	NULL
using	NULL
the	NULL
following	NULL
PCR	NULL
conditions	NULL
:	NULL
denaturation	NULL
at	NULL
95Â°C	NULL
for	NULL
1	NULL
minute	NULL
,	NULL
annealing	NULL
at	NULL
65Â°C	NULL
for	NULL
2	NULL
minutes	NULL
,	NULL
and	NULL
extension	NULL
at	NULL
76Â°C	NULL
for	NULL
3	NULL
minutes	NULL
,	NULL
with	NULL
an	NULL
increase	NULL
of	NULL
the	NULL
extension	NULL
time	NULL
of	NULL
5	NULL
seconds	NULL
after	NULL
each	NULL
cycle	NULL
(	NULL
17	NULL
cycles	NULL
)	NULL
.	NULL

The	NULL
final	NULL
amplification	NULL
was	NULL
performed	NULL
with	NULL
primer	NULL
3	NULL
,	NULL
which	NULL
had	NULL
been	NULL
labeled	NULL
with	NULL
y-*P	NULL
adenosine	NULL
triphosphate	NULL
(	NULL
ATP	NULL
)	NULL
using	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
Boehringer-Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

Two	NULL
cycles	NULL
using	NULL
the	NULL
following	NULL
conditions	NULL
were	NULL
performed	NULL
:	NULL
denaturation	NULL
at	NULL
95Â°C	NULL
for	NULL
1	NULL
minute	NULL
,	NULL
annealing	NULL
at	NULL
69Â°C	NULL
for	NULL
2	NULL
minutes	NULL
,	NULL
and	NULL
extension	NULL
at	NULL
76Â°C	NULL
for	NULL
10	NULL
minutes	NULL
.	NULL

In	NULL
both	NULL
amplification	NULL
steps	NULL
Vent	NULL
polymerase	NULL
was	NULL
used	NULL
.	NULL

After	NULL
phenol/chloroform	NULL
extraction	NULL
and	NULL
ethanol	NULL
precipitation	NULL
one	NULL
tenth	NULL
of	NULL
the	NULL
reaction	NULL
volume	NULL
was	NULL
loaded	NULL
on	NULL
a	NULL
6	NULL
%	NULL
acrylamide	NULL
sequencing	NULL
gel	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
under	NULL
vacuum	NULL
and	NULL
exposed	NULL
for	NULL
autoradiography	NULL
for	NULL
12	NULL
to	NULL
24	NULL
hours	NULL
at	NULL
-70Â°C	NULL
.	NULL

The	NULL
nucleotide	NULL
sequences	NULL
of	NULL
the	NULL
primers	NULL
used	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
Primer	NULL
set	NULL
1	NULL
visualizes	NULL
site	NULL
1	NULL
by	NULL
amplifying	NULL
the	NULL
lower	NULL
strand	NULL
of	NULL
the	NULL
CD19	NULL
promoter	NULL
;	NULL
primer	NULL
1	NULL
,	NULL
5-GGTAGCATGAGCATGCCAGGG-3	NULL
;	NULL
primer	NULL
-	NULL
2	NULL
,	NULL
5'-GGGTCTTTTTCAAGAAGTGAAACCTGGTAA-GGCAG-3	NULL
'	NULL
;	NULL
primer	NULL
3	NULL
,	NULL
5-GGTCTTTTITCAAGAAGTGAAACCT-GGTAAGGCAGAAACTTTTTTTGCA	NULL
CCTCCTT	NULL
CAGCTA-TGGTAAGTGT-3	NULL
'	NULL
.	NULL

Primer	NULL
set	NULL
2	NULL
visualizes	NULL
site	NULL
1	NULL
by	NULL
amplifying	NULL
the	NULL
upper	NULL
strand	NULL
;	NULL
primer	NULL
1	NULL
,	NULL
5	NULL
``	NULL
-CAAAACCATTCTATACCTTATCCA-TCACCTCC-3	NULL
'	NULL
;	NULL
primer	NULL
2	NULL
,	NULL
5-GATTCCTTACCTGAGTCTCCA-AGGCCTC-3	NULL
'	NULL
;	NULL
primer	NULL
3	NULL
,	NULL
5-GATTCCTTACCTGAGTCTCCA-AGGCCTCAAATCTCAAGGGCTG-3	NULL
'	NULL
.	NULL

Primer	NULL
set	NULL
3	NULL
visualizes	NULL
site	NULL
2	NULL
by	NULL
amplifying	NULL
the	NULL
lower	NULL
strand	NULL
of	NULL
the	NULL
CD19	NULL
promoter	NULL
;	NULL
primer	NULL
1	NULL
,	NULL
5-TCCAGGCCTGAAGATGAAATCGCTG-3	NULL
'	NULL
;	NULL
primer	NULL
2	NULL
,	NULL
5-CAT-CAGGTGACAGGAAATCAGTAGCTTCTGCTAC-3	NULL
'	NULL
;	NULL
primer	NULL
3	NULL
,	NULL
5-TGACAGGAAATCAGTAGCTTCTGCTACCCTGGGCTT-CGCTCCAATT-3	NULL
'	NULL
.	NULL

Preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
and	NULL
EMSA	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
.	NULL
``	NULL

Probes	NULL
for	NULL
EMSA	NULL
were	NULL
synthesized	NULL
as	NULL
complementary	NULL
oligonucleotides	NULL
with	NULL
a	NULL
1	NULL
base	NULL
pair	NULL
(	NULL
bp	NULL
)	NULL
overhang	NULL
.	NULL

One	NULL
hundred	NULL
micrograms	NULL
of	NULL
each	NULL
complementary	NULL
strand	NULL
were	NULL
ethanol	NULL
precipitated	NULL
together	NULL
,	NULL
and	NULL
annealed	NULL
in	NULL
a	NULL
PCR	NULL
machine	NULL
for	NULL
10	NULL
3985	NULL
minutes	NULL
at	NULL
each	NULL
of	NULL
the	NULL
following	NULL
temperatures	NULL
:	NULL
68Â°C	NULL
,	NULL
55Â°C	NULL
,	NULL
37Â°C	NULL
,	NULL
and	NULL
24Â°C	NULL
.	NULL

The	NULL
annealed	NULL
oligonucleotides	NULL
were	NULL
gel	NULL
purified	NULL
on	NULL
a	NULL
15	NULL
%	NULL
polyacrylamide	NULL
1	NULL
%	NULL
TBE	NULL
(	NULL
Tris-Borate-EDTA	NULL
)	NULL
gel	NULL
.	NULL

The	NULL
5	NULL
``	NULL
ends	NULL
of	NULL
the	NULL
gel	NULL
shift	NULL
probes	NULL
were	NULL
radiolabeled	NULL
with	NULL
y	NULL
P-ATP	NULL
using	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
Boehringer-Mannheim	NULL
)	NULL
.	NULL

After	NULL
labeling	NULL
at	NULL
37Â°C	NULL
for	NULL
30	NULL
minutes	NULL
the	NULL
probes	NULL
were	NULL
purified	NULL
over	NULL
a	NULL
G50	NULL
spin	NULL
column	NULL
(	NULL
5'-3	NULL
``	NULL
Inc	NULL
,	NULL
Boulder	NULL
,	NULL
CO	NULL
)	NULL
.	NULL

For	NULL
EMSA	NULL
0.5	NULL
ng	NULL
of	NULL
the	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
4	NULL
to	NULL
8	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
or	NULL
1.5	NULL
of	NULL
in	NULL
vitro	NULL
translated	NULL
protein	NULL
in	NULL
a	NULL
binding	NULL
reaction	NULL
that	NULL
contained	NULL
20	NULL
mmol/L	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
50	NULL
mmol/L	NULL
KCI	NULL
,	NULL
1	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
1	NULL
mmol/L	NULL
DTT	NULL
,	NULL
0.5	NULL
mmol/	NULL
L	NULL
MgCL	NULL
;	NULL
,	NULL
0.1	NULL
%	NULL
tween	NULL
20	NULL
,	NULL
5	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
1	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
20	NULL
gL	NULL
.	NULL

One	NULL
hundred	NULL
nanograms	NULL
of	NULL
unlabeled	NULL
probe	NULL
was	NULL
used	NULL
as	NULL
competitor	NULL
DNAs	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
20	NULL
minutes	NULL
.	NULL

For	NULL
antibody	NULL
supershift	NULL
experiments	NULL
,	NULL
an	NULL
anti-TFE3	NULL
antiserum	NULL
(	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr	NULL
Kathryn	NULL
Calame	NULL
,	NULL
Columbia	NULL
University	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
anti-USF1	NULL
,	NULL
anti-USF2	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
anti-Pip	NULL
(	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr	NULL
Harinder	NULL
Singh	NULL
,	NULL
University	NULL
of	NULL
Chicago	NULL
,	NULL
Chicago	NULL
,	NULL
IL	NULL
)	NULL
or	NULL
preimmune	NULL
serum	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extract	NULL
in	NULL
the	NULL
binding	NULL
buffer	NULL
for	NULL
20	NULL
minutes	NULL
on	NULL
ice	NULL
.	NULL

After	NULL
addition	NULL
of	NULL
the	NULL
gel	NULL
shift	NULL
probe	NULL
the	NULL
samples	NULL
were	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
an	NULL
additional	NULL
20	NULL
minutes	NULL
.	NULL

For	NULL
the	NULL
PU.1	NULL
depletion	NULL
experiment	NULL
10	NULL
gL	NULL
of	NULL
anti-PU.1	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
or	NULL
a	NULL
control	NULL
antiserum	NULL
were	NULL
incubated	NULL
at	NULL
4Â°C	NULL
with	NULL
16	NULL
uL	NULL
of	NULL
binding	NULL
buffer	NULL
and	NULL
2	NULL
uL	NULL
of	NULL
nuclear	NULL
extract	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
goat	NULL
antirabbit	NULL
Ig	NULL
coupled	NULL
to	NULL
magnetic	NULL
beads	NULL
(	NULL
Dynal	NULL
,	NULL
Oslo	NULL
,	NULL
Norway	NULL
)	NULL
.	NULL

One	NULL
hour	NULL
later	NULL
the	NULL
magnetic	NULL
beads	NULL
were	NULL
removed	NULL
,	NULL
and	NULL
labeled	NULL
probe	NULL
and	NULL
1	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
were	NULL
added	NULL
to	NULL
the	NULL
PU.1-depleted	NULL
extract	NULL
.	NULL

All	NULL
gel	NULL
shift	NULL
samples	NULL
were	NULL
electrophoresed	NULL
on	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
using	NULL
high	NULL
ionic	NULL
strength	NULL
buffer	NULL
(	NULL
50	NULL
mmol/L	NULL
Tris	NULL
pH	NULL
7.5	NULL
,	NULL
380	NULL
mmol/L	NULL
glycine	NULL
,	NULL
and	NULL
2	NULL
mmol/L	NULL
EDTA	NULL
)	NULL
at	NULL
25	NULL
mA	NULL
for	NULL
2	NULL
hours	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
under	NULL
vacuum	NULL
and	NULL
exposed	NULL
for	NULL
autoradiography	NULL
for	NULL
1	NULL
to	NULL
3	NULL
hours	NULL
.	NULL

The	NULL
following	NULL
EMSA	NULL
probes	NULL
were	NULL
used	NULL
(	NULL
only	NULL
the	NULL
nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
upper	NULL
strand	NULL
of	NULL
each	NULL
probe	NULL
is	NULL
shown	NULL
)	NULL
:	NULL
CD20	NULL
#	NULL
1	NULL
,	NULL
TCCTGTCAC-CTGATGTCTATC	NULL
;	NULL
-	NULL
CD201Mul	NULL
,	NULL
TCCTGTATCCGCATGTCT-ATC	NULL
;	NULL
4E3	NULL
,	NULL
GATTGCGTCATGTGGTCTCT	NULL
;	NULL
Â£E5	NULL
,	NULL
GATTGCTGC-AGGTGTTCTCT	NULL
;	NULL
CD20	NULL
#	NULL
2	NULL
,	NULL
GTCTTTTTTCAAGAAGTGAACCT	NULL
;	NULL
CD20	NULL
#	NULL
2	NULL
Mu	NULL
,	NULL
GTCTTTTTTCAAGAAGTCGTACCT	NULL
;	NULL
AB	NULL
,	NULL
AAA-TAAAAGGAAGTGAAACCAAG	NULL
.	NULL

e	NULL
Plasmids	NULL
and	NULL
in	NULL
vitro	NULL
translation	NULL
.	NULL

A	NULL
fragment	NULL
containing	NULL
bp	NULL
-425/+52	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
was	NULL
amplified	NULL
by	NULL
PCR	NULL
from	NULL
an	NULL
828-bp	NULL
promoter	NULL
fragment	NULL
that	NULL
was	NULL
previously	NULL
subcloned	NULL
into	NULL
the	NULL
polylinker	NULL
of	NULL
the	NULL
pGEM	NULL
4-CAT	NULL
plasmid	NULL
.	NULL
``	NULL

The	NULL
PCR	NULL
fragment	NULL
was	NULL
ligated	NULL
into	NULL
the	NULL
Smal	NULL
site	NULL
of	NULL
the	NULL
polylinker	NULL
of	NULL
the	NULL
luciferase	NULL
expression	NULL
vector	NULL
pGL3Basic	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
by	NULL
T-A	NULL
overhang	NULL
cloning	NULL
.	NULL

The	NULL
orientation	NULL
and	NULL
the	NULL
nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
resulting	NULL
plasmid	NULL
,	NULL
termed	NULL
pGL3-CD20-425	NULL
,	NULL
were	NULL
verified	NULL
by	NULL
DNA	NULL
sequenc-ing	NULL
.	NULL

A	NULL
plasmid	NULL
containing	NULL
PU.1	NULL
cDNA	NULL
and	NULL
the	NULL
PU.1	NULL
expression	NULL
vector	NULL
PU.1-pECE	NULL
were	NULL
a	NULL
gift	NULL
from	NULL
Dr	NULL
R.	NULL
Maki	NULL
(	NULL
LaJolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
vector	NULL
pBS-ATG/TFE3	NULL
and	NULL
the	NULL
TFE3	NULL
expression	NULL
vector	NULL
pSV2-TFE3	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
K.	NULL
Calame	NULL
(	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

The	NULL
vectors	NULL
for	NULL
in	NULL
vitro	NULL
translation	NULL
and	NULL
expression	NULL
of	NULL
Pip	NULL
were	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr	NULL
H.	NULL
Singh	NULL
(	NULL
Chicago	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

The	NULL
USF	NULL
expression	NULL
vector	NULL
CMV-USF	NULL
was	NULL
provided	NULL
by	NULL
Dr	NULL
R.	NULL
Roeder	NULL
(	NULL
Rockefeller	NULL
University	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
)	NULL
and	NULL
the	NULL
Oct-2	NULL
expression	NULL
vector	NULL
CMV-Oct-2	NULL
was	NULL
obtained	NULL
from	NULL
L.	NULL
Staudt	NULL
(	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

For	NULL
in	NULL
vitro	NULL
translations	NULL
1	NULL
ug	NULL
of	NULL
the	NULL
respective	NULL
plasmid	NULL
was	NULL
in	NULL
vitro	NULL
transcribed	NULL
and	NULL
translated	NULL
using	NULL
the	NULL
appropriate	NULL
RNA	NULL
polymerase	NULL
and	NULL
a	NULL
TnT	NULL
lysate	NULL
coupled	NULL
Transcription/Translation	NULL
kit	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

The	NULL
resulting	NULL
[	NULL
*S-methionine	NULL
labeled	NULL
proteins	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-polyacrylamide	NULL
electrophoresis	NULL
before	NULL
use	NULL
in	NULL
mobility	NULL
shift	NULL
experiments	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
pGL3-CD20-425	NULL
construct	NULL
were	NULL
generated	NULL
using	NULL
35-bp	NULL
oligonucleotides	NULL
carrying	NULL
4-bp	NULL
mutations	NULL
and	NULL
a	NULL
mutagenesis	NULL
kit	NULL
from	NULL
Pharmacia	NULL
.	NULL

The	NULL
following	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3986	NULL
mutations	NULL
were	NULL
introduced	NULL
:	NULL
the	NULL
E-Box	NULL
at	NULL
bp	NULL
-45	NULL
was	NULL
changed	NULL
from	NULL
CACCTG	NULL
to	NULL
AGCCGA	NULL
and	NULL
the	NULL
PU.1/Pip	NULL
binding	NULL
site	NULL
was	NULL
altered	NULL
from	NULL
CAAGAAGTGAAACCT	NULL
to	NULL
CACTCCGTGAAACCT	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
mutated	NULL
constructs	NULL
was	NULL
confirmed	NULL
by	NULL
DNA	NULL
sequenc-ing	NULL
.	NULL

Transfection	NULL
and	NULL
luciferase	NULL
assay	NULL
.	NULL

-	NULL
For	NULL
transfections	NULL
all	NULL
plasmids	NULL
were	NULL
prepared	NULL
by	NULL
alkaline-SDS	NULL
method	NULL
followed	NULL
by	NULL
purification	NULL
over	NULL
Qiagen	NULL
columns	NULL
(	NULL
Qiagen	NULL
,	NULL
Chatsworth	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

HS-Sultan	NULL
,	NULL
U266	NULL
,	NULL
and	NULL
RPMI	NULL
8226	NULL
and	NULL
Jurkat	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
10	NULL
mmol/L	NULL
HEPES	NULL
buffer	NULL
,	NULL
pH	NULL
7.5	NULL
.	NULL

Five	NULL
micrograms	NULL
of	NULL
reporter	NULL
gene	NULL
pGL3-CD20-425	NULL
and	NULL
1	NULL
ug	NULL
of	NULL
the	NULL
3-Gal	NULL
control	NULL
plasmid	NULL
were	NULL
added	NULL
to	NULL
5	NULL
%	NULL
10Â°	NULL
cells	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
200	NULL
gL	NULL
medium	NULL
and	NULL
placed	NULL
on	NULL
ice	NULL
.	NULL

Electroporation	NULL
was	NULL
performed	NULL
by	NULL
using	NULL
a	NULL
Bio-Rad	NULL
(	NULL
Hercules	NULL
,	NULL
CA	NULL
)	NULL
Gene	NULL
Pulser	NULL
(	NULL
0.4	NULL
cm	NULL
cuvettes	NULL
)	NULL
at	NULL
250V/960	NULL
gFD	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
5	NULL
to	NULL
10	NULL
minutes	NULL
,	NULL
placed	NULL
in	NULL
complete	NULL
medium	NULL
,	NULL
and	NULL
cultured	NULL
for	NULL
16	NULL
hours	NULL
before	NULL
performing	NULL
luciferase	NULL
assays	NULL
.	NULL

NIH3T3	NULL
cells	NULL
were	NULL
transfected	NULL
using	NULL
the	NULL
calcium	NULL
phosphate	NULL
method	NULL
.	NULL

Six	NULL
micrograms	NULL
of	NULL
reporter	NULL
plasmid	NULL
,	NULL
2.5	NULL
ug	NULL
of	NULL
each	NULL
expression	NULL
vector	NULL
,	NULL
and	NULL
1	NULL
ug	NULL
of	NULL
B-Gal	NULL
control	NULL
vector	NULL
were	NULL
mixed	NULL
with	NULL
CaCl	NULL
;	NULL
and	NULL
2	NULL
%	NULL
HEPES	NULL
buffered	NULL
saline	NULL
and	NULL
added	NULL
to	NULL
the	NULL
NIH3T3	NULL
cells	NULL
on	NULL
a	NULL
50	NULL
%	NULL
to	NULL
60	NULL
%	NULL
confluent	NULL
plate	NULL
.	NULL

The	NULL
total	NULL
amount	NULL
of	NULL
transfected	NULL
DNA	NULL
was	NULL
kept	NULL
constant	NULL
by	NULL
adding	NULL
empty	NULL
expression	NULL
vector	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
cultured	NULL
overnight	NULL
,	NULL
washed	NULL
twice	NULL
in	NULL
medium	NULL
,	NULL
and	NULL
harvested	NULL
after	NULL
16	NULL
hours	NULL
.	NULL

For	NULL
luciferase	NULL
assay	NULL
the	NULL
cells	NULL
were	NULL
pelleted	NULL
and	NULL
resuspended	NULL
in	NULL
50	NULL
uL	NULL
of	NULL
lysis	NULL
buffer	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

After	NULL
one	NULL
freeze/thaw	NULL
cycle	NULL
the	NULL
lysates	NULL
were	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
using	NULL
luciferase	NULL
substrate	NULL
(	NULL
Promega	NULL
)	NULL
and	NULL
a	NULL
luminometer	NULL
(	NULL
Analytical	NULL
Luminescence	NULL
Laboratory	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

B-Gal	NULL
activity	NULL
was	NULL
measured	NULL
from	NULL
the	NULL
same	NULL
lysates	NULL
using	NULL
galactan	NULL
chemiluminescent	NULL
substrate	NULL
(	NULL
Tropix	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
in	NULL
the	NULL
same	NULL
lum-inometer	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
.	NULL

-	NULL
Whole	NULL
cell	NULL
lysates	NULL
from	NULL
the	NULL
different	NULL
cell	NULL
lines	NULL
were	NULL
prepared	NULL
in	NULL
RIPA	NULL
buffer	NULL
(	NULL
150	NULL
mmol/L	NULL
NaCI	NULL
,	NULL
1	NULL
%	NULL
NP-40	NULL
,	NULL
0.5	NULL
%	NULL
deoxycholic	NULL
acid	NULL
(	NULL
DOC	NULL
)	NULL
,	NULL
0.1	NULL
%	NULL
SDS	NULL
,	NULL
50	NULL
mmol/L	NULL
Tris	NULL
,	NULL
pH	NULL
8	NULL
)	NULL
and	NULL
protein	NULL
concentrations	NULL
measured	NULL
by	NULL
the	NULL
Bradford	NULL
assay	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

One	NULL
hundred	NULL
micrograms	NULL
of	NULL
lysate	NULL
were	NULL
separated	NULL
by	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
SDS-PAGE	NULL
)	NULL
,	NULL
transferred	NULL
to	NULL
a	NULL
nitrocellulose	NULL
membrane	NULL
,	NULL
and	NULL
blocked	NULL
with	NULL
Tween-Tris-buffered	NULL
saline	NULL
(	NULL
TTBS	NULL
)	NULL
and	NULL
10	NULL
%	NULL
milk	NULL
for	NULL
one	NULL
hour	NULL
.	NULL

The	NULL
immunoblots	NULL
were	NULL
then	NULL
incubated	NULL
with	NULL
rabbit	NULL
anti-PU.1	NULL
antiserum	NULL
(	NULL
1:500	NULL
;	NULL
Santa	NULL
Cruz	NULL
Biotechnologies	NULL
)	NULL
in	NULL
TTBS	NULL
and	NULL
5	NULL
%	NULL
milk	NULL
.	NULL

This	NULL
was	NULL
followed	NULL
by	NULL
incubation	NULL
with	NULL
biotinylated	NULL
antirabbit	NULL
monoclonal	NULL
antibody	NULL
(	NULL
1:5,000	NULL
)	NULL
,	NULL
and	NULL
horse	NULL
radish	NULL
peroxidase	NULL
(	NULL
HRP	NULL
)	NULL
-conjugated	NULL
strep-tavidin	NULL
(	NULL
1:10,000	NULL
)	NULL
before	NULL
detection	NULL
.	NULL

All	NULL
immunoblots	NULL
were	NULL
detected	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
Amersham	NULL
,	NULL
Buckinghamshire	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

RESULTS	NULL
B-cell-specific	NULL
DNA	NULL
protein	NULL
interactions	NULL
in	NULL
the	NULL
proximal	NULL
CD20	NULL
gene	NULL
promoter	NULL
.	NULL

To	NULL
identify	NULL
cis-elements	NULL
likely	NULL
important	NULL
in	NULL
lineage-specific	NULL
expression	NULL
of	NULL
CD20	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
proximal	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
CD20	NULL
gene	NULL
by	NULL
in	NULL
vivo	NULL
footprinting	NULL
using	NULL
either	NULL
in	NULL
vitro	NULL
or	NULL
in	NULL
vivo	NULL
methylated	NULL
DNA	NULL
.	NULL

By	NULL
comparing	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
methylated	NULL
DNA	NULL
from	NULL
the	NULL
CD20-positive	NULL
human	NULL
B-cell	NULL
line	NULL
,	NULL
HS-Sultan	NULL
,	NULL
a	NULL
human	NULL
plasmacytoma	NULL
cell	NULL
line	NULL
,	NULL
we	NULL
found	NULL
an	NULL
in	NULL
vivo	NULL
protected	NULL
region	NULL
on	NULL
both	NULL
strands	NULL
located	NULL
at	NULL
approximately	NULL
bp	NULL
-45	NULL
(	NULL
Fig	NULL
1A	NULL
,	NULL
lane	NULL
1	NULL
versus	NULL
2	NULL
,	NULL
lower	NULL
strand	NULL
of	NULL
the	NULL
promoter	NULL
amplified	NULL
and	NULL
Fig	NULL
1C	NULL
,	NULL
lane	NULL
1	NULL
versus	NULL
2	NULL
,	NULL
upper	NULL
strand	NULL
amplified	NULL
)	NULL
.	NULL

We	NULL
failed	NULL
to	NULL
detect	NULL
a	NULL
similar	NULL
footprinted	NULL
region	NULL
with	NULL
in	NULL
vivo	NULL
methylated	NULL
DNA	NULL
prepared	NULL
from	NULL
HeLa	NULL
cells	NULL
(	NULL
Fig	NULL
1C	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
from	NULL
a	NULL
CD20-negative	NULL
pre-B-cell	NULL
line	NULL
(	NULL
Fig	NULL
1B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

In	NULL
vivo	NULL
methylated	NULL
DNA	NULL
from	NULL
another	NULL
CD20-positive	NULL
B-cell	NULL
line	NULL
,	NULL
HIMMELMANN	NULL
ET	NULL
AL	NULL
BJA-B	NULL
,	NULL
also	NULL
contained	NULL
a	NULL
footprint	NULL
at	NULL
this	NULL
location	NULL
(	NULL
Fig	NULL
1B	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

The	NULL
protected	NULL
region	NULL
at	NULL
-45	NULL
will	NULL
be	NULL
referred	NULL
to	NULL
as	NULL
site	NULL
1	NULL
and	NULL
spanned	NULL
the	NULL
nucleotide	NULL
sequence	NULL
CCTGTCACC-TGA	NULL
(	NULL
Fig	NULL
1D	NULL
)	NULL
.	NULL

We	NULL
identified	NULL
another	NULL
in	NULL
vivo	NULL
protected	NULL
region	NULL
located	NULL
at	NULL
-160	NULL
by	NULL
comparing	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
methylated	NULL
DNA	NULL
from	NULL
HS-Sultan	NULL
cells	NULL
(	NULL
Fig	NULL
2A	NULL
,	NULL
compare	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
with	NULL
in	NULL
vivo	NULL
methylated	NULL
DNA	NULL
from	NULL
BJA-B	NULL
cells	NULL
(	NULL
Fig	NULL
2B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

The	NULL
second	NULL
in	NULL
vivo	NULL
footprint	NULL
again	NULL
appeared	NULL
B-cell	NULL
specific	NULL
because	NULL
no	NULL
footprint	NULL
was	NULL
seen	NULL
using	NULL
DNA	NULL
prepared	NULL
from	NULL
the	NULL
T-lymphocyte	NULL
cell	NULL
line	NULL
Jurkat	NULL
or	NULL
HeLa	NULL
cells	NULL
(	NULL
Fig	NULL
2A	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
did	NULL
not	NULL
detect	NULL
the	NULL
footprinted	NULL
region	NULL
in	NULL
DNA	NULL
prepared	NULL
from	NULL
the	NULL
CD20-negative	NULL
pre-B-cell	NULL
line	NULL
PB697	NULL
(	NULL
Fig	NULL
2B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
protected	NULL
region	NULL
at	NULL
-160	NULL
will	NULL
be	NULL
referred	NULL
to	NULL
as	NULL
site	NULL
2	NULL
and	NULL
spanned	NULL
the	NULL
nucleotide	NULL
sequence	NULL
GAAGTG	NULL
(	NULL
Fig	NULL
1D	NULL
)	NULL
.	NULL

The	NULL
proximal	NULL
cis-element	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
binds	NULL
members	NULL
of	NULL
the	NULL
bHLHZ	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
transcription	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
binding	NULL
to	NULL
the	NULL
promoter	NULL
site	NULL
1	NULL
,	NULL
we	NULL
generated	NULL
a	NULL
double	NULL
stranded	NULL
oligonucleotide	NULL
probe	NULL
termed	NULL
CD20	NULL
#	NULL
1	NULL
that	NULL
encompassed	NULL
the	NULL
presumptive	NULL
protein	NULL
binding	NULL
site	NULL
localized	NULL
by	NULL
in	NULL
vivo	NULL
footprinting	NULL
.	NULL

EMSA	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
B-cell	NULL
lines	NULL
visualized	NULL
a	NULL
DNA-protein	NULL
doublet	NULL
consisting	NULL
of	NULL
an	NULL
intense	NULL
slow	NULL
migrating	NULL
band	NULL
and	NULL
a	NULL
less	NULL
intense	NULL
faster	NULL
migrating	NULL
band	NULL
(	NULL
together	NULL
referred	NULL
to	NULL
as	NULL
complex	NULL
1	NULL
)	NULL
.	NULL

Adding	NULL
an	NULL
excess	NULL
amount	NULL
of	NULL
the	NULL
unlabeled	NULL
probe	NULL
effectively	NULL
competed	NULL
detection	NULL
of	NULL
the	NULL
complex	NULL
(	NULL
Fig	NULL
3A	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Complex	NULL
1	NULL
is	NULL
not	NULL
unique	NULL
to	NULL
B-cell	NULL
nuclear	NULL
extracts	NULL
as	NULL
we	NULL
observed	NULL
a	NULL
complex	NULL
of	NULL
similar	NULL
mobility	NULL
using	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
lines	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
sequence	NULL
of	NULL
probe	NULL
CD20	NULL
#	NULL
1	NULL
contained	NULL
a	NULL
potential	NULL
E-Box	NULL
element	NULL
,	NULL
we	NULL
performed	NULL
further	NULL
EMSA	NULL
by	NULL
using	NULL
competitors	NULL
as	NULL
unlabeled	NULL
probes	NULL
containing	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
potential	NULL
E-Box	NULL
and	NULL
probes	NULL
containing	NULL
the	NULL
E3	NULL
site	NULL
or	NULL
the	NULL
E5	NULL
element	NULL
from	NULL
the	NULL
IgH	NULL
chain	NULL
intronic	NULL
enhancer	NULL
.	NULL

The	NULL
wE3	NULL
probe	NULL
,	NULL
but	NULL
not	NULL
the	NULL
E5	NULL
probe	NULL
,	NULL
competed	NULL
binding	NULL
(	NULL
Fig	NULL
3A	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
CD20	NULL
#	NULL
1	NULL
probe	NULL
with	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
potential	NULL
E-Box	NULL
element	NULL
failed	NULL
to	NULL
compete	NULL
formation	NULL
of	NULL
complex	NULL
1	NULL
(	NULL
Fig	NULL
3A	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Performing	NULL
the	NULL
EMSA	NULL
with	NULL
a	NULL
labeled	NULL
mE3	NULL
probe	NULL
yielded	NULL
a	NULL
complex	NULL
with	NULL
an	NULL
identical	NULL
mobility	NULL
to	NULL
that	NULL
of	NULL
complex	NULL
1	NULL
and	NULL
formation	NULL
of	NULL
the	NULL
complex	NULL
was	NULL
competed	NULL
by	NULL
the	NULL
CD20	NULL
probe	NULL
,	NULL
but	NULL
not	NULL
by	NULL
the	NULL
4E5	NULL
element	NULL
(	NULL
Fig	NULL
3A	NULL
,	NULL
lanes	NULL
6	NULL
to	NULL
9	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
E3	NULL
and	NULL
the	NULL
E5	NULL
element	NULL
of	NULL
the	NULL
IgH	NULL
intronic	NULL
enhancer	NULL
bind	NULL
distinct	NULL
subfamilies	NULL
of	NULL
basic	NULL
helix-loop-helix	NULL
(	NULL
bHLH	NULL
)	NULL
proteins	NULL
.	NULL
``	NULL

The	NULL
E3	NULL
element	NULL
binds	NULL
bHLHZ	NULL
DNA-binding	NULL
proteins	NULL
such	NULL
as	NULL
TFE3	NULL
,	NULL
TFEB	NULL
,	NULL
and	NULL
USF	NULL
,	NULL
whereas	NULL
the	NULL
E5	NULL
site	NULL
interacts	NULL
with	NULL
members	NULL
of	NULL
class	NULL
I	NULL
bHLH	NULL
family	NULL
,	NULL
such	NULL
as	NULL
the	NULL
products	NULL
of	NULL
the	NULL
EZA	NULL
and	NULL
E2-2	NULL
genes	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
bHLHZ	NULL
proteins	NULL
bound	NULL
the	NULL
CD20	NULL
E	NULL
Box	NULL
we	NULL
translated	NULL
TFE3	NULL
in	NULL
vitro	NULL
and	NULL
performed	NULL
an	NULL
EMSA	NULL
with	NULL
the	NULL
CD20	NULL
#	NULL
1	NULL
probe	NULL
and	NULL
the	NULL
probe	NULL
containing	NULL
the	NULL
E3	NULL
element	NULL
of	NULL
the	NULL
IgH	NULL
gene	NULL
enhancer	NULL
.	NULL

We	NULL
detected	NULL
a	NULL
complex	NULL
of	NULL
identical	NULL
mobility	NULL
with	NULL
either	NULL
probe	NULL
that	NULL
was	NULL
effectively	NULL
competed	NULL
by	NULL
the	NULL
respective	NULL
unlabeled	NULL
probe	NULL
(	NULL
Fig	NULL
3B	NULL
,	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
a	NULL
TFE3-specific	NULL
antiserum	NULL
,	NULL
but	NULL
not	NULL
a	NULL
preimmune	NULL
serum	NULL
,	NULL
abolished	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
complex	NULL
(	NULL
Fig	NULL
3B	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
and	NULL
8	NULL
)	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
the	NULL
CD20	NULL
probe	NULL
binds	NULL
a	NULL
member	NULL
of	NULL
the	NULL
bHLHZ	NULL
protein	NULL
family	NULL
;	NULL
however	NULL
,	NULL
complex	NULL
1	NULL
generated	NULL
by	NULL
incubating	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

REGULATION	NULL
OF	NULL
CD20	NULL
PROMOTER	NULL
3987	NULL
A	NULL
B	NULL
C	NULL
J	NULL
e	NULL
1	NULL
2	NULL
1Â°	NULL
2	NULL
3	NULL
las	NULL
L	NULL
19-	NULL
%	NULL
-31-	NULL
-61-	NULL
m	NULL
-31-	NULL
s	NULL
42	NULL
-	NULL
ite	NULL
47	NULL
-	NULL
18mg	NULL
1	NULL
P	NULL
Â®	NULL
Â©	NULL
_	NULL
:	NULL
IS\te	NULL
1Â°	NULL
-37	NULL
J	NULL
Site	NULL
1	NULL
47	NULL
Â»	NULL
=	NULL
-49	NULL
--	NULL
Win	NULL
-	NULL
Wik	NULL
-57-_	NULL
Â«	NULL
ten	NULL
Hs	NULL
57	NULL
pea	NULL
-66	NULL
-	NULL
-8	NULL
-	NULL
Â«	NULL
tt	NULL
Â«	NULL
Â»	NULL
HHP	NULL
-66	NULL
-	NULL
(	NULL
(	NULL
le	NULL
.	NULL

3	NULL
-74-	NULL
-	NULL
we	NULL
*	NULL
Fig	NULL
1	NULL
.	NULL

In	NULL
vivo	NULL
footprinting	NULL
of	NULL
the	NULL
proximal	NULL
CD20	NULL
~	NULL
``	NULL
*-	NULL
Â®	NULL
@	NULL
.	NULL

promoter	NULL
by	NULL
amplifying	NULL
either	NULL
the	NULL
coding	NULL
or	NULL
the	NULL
non-	NULL
g	NULL
-81-	NULL
+15-	NULL
i	NULL
coding	NULL
strand	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Naked	NULL
genomic	NULL
DNA	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
_	NULL
1~	NULL
-	NULL
.	NULL

Â¥	NULL
intact	NULL
cells	NULL
from	NULL
the	NULL
B-cell	NULL
line	NULL
HS-Sultan	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
<	NULL
i	NULL
>	NULL
4	NULL
were	NULL
treated	NULL
with	NULL
DMS	NULL
and	NULL
in	NULL
vitro	NULL
or	NULL
in	NULL
vivo	NULL
foot-	NULL
+25-	NULL
*	NULL
â¬	NULL
+	NULL
prints	NULL
were	NULL
visualized	NULL
by	NULL
ligation	NULL
mediated	NULL
PCR	NULL
us-	NULL
C	NULL
ing	NULL
primer	NULL
set	NULL
1	NULL
.	NULL

The	NULL
numbers	NULL
on	NULL
the	NULL
left	NULL
correspond	NULL
oc-	NULL
&	NULL
&	NULL
ae	NULL
-96-	NULL
Â®	NULL
a	NULL
Â»	NULL
dlt	NULL
cau	NULL
.	NULL

*	NULL
to	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
as	NULL
shown	NULL
in	NULL
Â£	NULL
5	NULL
o	NULL
+1	NULL
4.04	NULL
%	NULL
%	NULL
panel	NULL
D.	NULL
The	NULL
in	NULL
vivo	NULL
protected	NULL
residues	NULL
are	NULL
desig-	NULL
L	NULL
_	NULL
iP	NULL
z	NULL
<	NULL
%	NULL
9L	NULL
O	NULL
&	NULL
nated	NULL
site	NULL
1	NULL
and	NULL
are	NULL
surrounded	NULL
by	NULL
a	NULL
bracket	NULL
.	NULL

(	NULL
B	NULL
)	NULL
In	NULL
{	NULL
D4	NULL
m4	NULL
YRS	NULL
)	NULL
2	NULL
,	NULL
7:0	NULL
L2	NULL
,	NULL
Â®	NULL
vivo	NULL
footprinting	NULL
using	NULL
primer	NULL
set	NULL
1	NULL
over	NULL
the	NULL
region	NULL
â	NULL
34	NULL
9	NULL
â	NULL
-	NULL
â	NULL
$	NULL
3	NULL
;	NULL
indicated	NULL
was	NULL
performed	NULL
using	NULL
in	NULL
vivo	NULL
methylated	NULL
A	NULL
7C	NULL
DNA	NULL
from	NULL
the	NULL
following	NULL
cell	NULL
lines	NULL
:	NULL
lane	NULL
1	NULL
,	NULL
CD20-	NULL
gy	NULL
%	NULL
positive	NULL
B-cell	NULL
line	NULL
BJA-B	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
CD20	NULL
negative	NULL
pre-B-cell	NULL
line	NULL
PB697	NULL
.	NULL

(	NULL
C	NULL
)	NULL
In	NULL
vivo	NULL
footprinting	NULL
on	NULL
the	NULL
op-	NULL
D	NULL
posing	NULL
strand	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
was	NULL
performed	NULL
using	NULL
primer	NULL
set	NULL
#	NULL
2	NULL
.	NULL

Naked	NULL
DNA	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
intact	NULL
TTL	NULL
Bf	NULL
â	NULL
T-Bv	NULL
CTCs	NULL
,	NULL
R	NULL
,	NULL
cells	NULL
from	NULL
the	NULL
B-cell	NULL
line	NULL
HS-Sultan	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
the	NULL
-230	NULL
-	NULL
GTGGGGGCTG	NULL
CAGAAGTTCT	NULL
TCTAATTAAG	NULL
GTAGCATGAG	NULL
CATGCCAGGC	NULL
cervical	NULL
carcinoma	NULL
cell	NULL
line	NULL
HeLa	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
were	NULL
used	NULL
.	NULL

e	NULL
ov	NULL
ov	NULL
(	NULL
D	NULL
)	NULL
Nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
first	NULL
230	NULL
base	NULL
pairs	NULL
|	NULL
1839	NULL
-	NULL
AGTCCCTGGG	NULL
GTCTTTTTCA	NULL
AGAAGTGAAA	NULL
CCTGGTAAGG	NULL
CAGAAACTTT	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

Known	NULL
transcriptional	NULL
start	NULL
L	NULL
--	NULL
--	NULL
--	NULL
-PU	NULL
.	NULL
]	NULL

/Pip	NULL
...	NULL
...	NULL
.	NULL

1	NULL
sites	NULL
are	NULL
marked	NULL
with	NULL
an	NULL
arrow	NULL
(	NULL
1	NULL
)	NULL
,	NULL
a	NULL
nucleotide	NULL
residue	NULL
within	NULL
the	NULL
most	NULL
3	NULL
'	NULL
cluster	NULL
of	NULL
transcriptional	NULL
_	NULL
-	NULL
TTTTGCACCT	NULL
CCTTCAGCTA	NULL
TGGTAAGTGT	NULL
TAAACCAAAG	NULL
TAATTGGAGC	NULL
start	NULL
sites	NULL
is	NULL
designated	NULL
+1	NULL
.	NULL

Binding	NULL
sites	NULL
for	NULL
regulatory	NULL
proteins	NULL
as	NULL
determined	NULL
by	NULL
EMSA	NULL
and	NULL
in	NULL
vivo	NULL
v	NULL
vov	NULL
vvovldd	NULL
1d	NULL
4d	NULL
footprinting	NULL
are	NULL
surrounded	NULL
by	NULL
a	NULL
bracket	NULL
.	NULL

In	NULL
vivo	NULL
pro-	NULL
-	NULL
-80	NULL
_	NULL
GAAGCCCAGG	NULL
GTAGCAGAAG	NULL
CTACTGATTT	NULL
CCTGTCACCT	NULL
GATGTCTATC	NULL
tected	NULL
nucleotides	NULL
are	NULL
indicated	NULL
by	NULL
a	NULL
triangle	NULL
(	NULL
V	NULL
)	NULL
,	NULL
|	NULL
E-Box	NULL
!	NULL

nucleotides	NULL
rendered	NULL
hypersensitive	NULL
by	NULL
in	NULL
vivo	NULL
meth-	NULL
U	NULL
1	NULL
J	NULL
4	NULL
+11	NULL
4	NULL
HJ	NULL
444	NULL
4	NULL
4	NULL
-30	NULL
_	NULL
AGCGATTTCA	NULL
TCTTCAGGCC	NULL
TGGACTACAC	NULL
CACTCACCCT	NULL
CCCAGTGTGC	NULL
ylation	NULL
by	NULL
a	NULL
diamond	NULL
(	NULL
4	NULL
)	NULL
.	NULL

probe	NULL
CD20	NULL
#	NULL
1	NULL
with	NULL
BJA-B	NULL
nuclear	NULL
extract	NULL
(	NULL
Fig	NULL
3B	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
displayed	NULL
a	NULL
slower	NULL
mobility	NULL
than	NULL
the	NULL
TFE3	NULL
complex	NULL
suggesting	NULL
that	NULL
complex	NULL
1	NULL
contained	NULL
other	NULL
members	NULL
of	NULL
the	NULL
bHLHZ	NULL
protein	NULL
family	NULL
.	NULL

Because	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
USF	NULL
is	NULL
the	NULL
predominant	NULL
protein	NULL
binding	NULL
to	NULL
E3	NULL
sites	NULL
in	NULL
B-cell	NULL
nuclear	NULL
extracts	NULL
``	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
antiserum	NULL
to	NULL
USFI1	NULL
or	NULL
USF2	NULL
impaired	NULL
detection	NULL
of	NULL
complex	NULL
1	NULL
using	NULL
extracts	NULL
from	NULL
either	NULL
BJA-B	NULL
or	NULL
HS-Sultan	NULL
cells	NULL
.	NULL

With	NULL
BJA-B	NULL
the	NULL
addition	NULL
of	NULL
a	NULL
USF1	NULL
antiserum	NULL
markedly	NULL
impaired	NULL
detection	NULL
of	NULL
the	NULL
upper	NULL
band	NULL
of	NULL
complex	NULL
1	NULL
,	NULL
but	NULL
not	NULL
the	NULL
lower	NULL
band	NULL
.	NULL

The	NULL
USF2	NULL
antiserum	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
detection	NULL
of	NULL
either	NULL
band	NULL
(	NULL
Fig	NULL
3C	NULL
)	NULL
.	NULL

With	NULL
HS-Sultan	NULL
cells	NULL
complex	NULL
1	NULL
contained	NULL
a	NULL
single	NULL
band	NULL
whose	NULL
detection	NULL
was	NULL
blocked	NULL
by	NULL
the	NULL
USF1	NULL
antibody	NULL
.	NULL

Thus	NULL
,	NULL
USFL	NULL
is	NULL
a	NULL
major	NULL
component	NULL
of	NULL
complex	NULL
1	NULL
and	NULL
likely	NULL
interacts	NULL
with	NULL
the	NULL
proximal	NULL
portion	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
there	NULL
may	NULL
be	NULL
another	NULL
bHLHZ	NULL
family	NULL
member	NULL
that	NULL
is	NULL
present	NULL
in	NULL
BJA-B	NULL
cells	NULL
but	NULL
absent	NULL
from	NULL
HS-Sultan	NULL
cells	NULL
.	NULL

A	NULL
protein	NULL
complex	NULL
containing	NULL
the	NULL
transcription	NULL
factor	NULL
PU.1	NULL
binds	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

The	NULL
protein	NULL
binding	NULL
site	NULL
identified	NULL
by	NULL
in	NULL
vivo	NULL
footprinting	NULL
at	NULL
bp	NULL
-160	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
was	NULL
also	NULL
analyzed	NULL
by	NULL
EMSA	NULL
using	NULL
an	NULL
oligonucleo-	NULL
tide	NULL
probe	NULL
(	NULL
CD20	NULL
#	NULL
2	NULL
)	NULL
spanning	NULL
the	NULL
site	NULL
.	NULL

With	NULL
this	NULL
probe	NULL
we	NULL
observed	NULL
two	NULL
complexes	NULL
,	NULL
a	NULL
more	NULL
intense	NULL
band	NULL
with	NULL
a	NULL
slower	NULL
mobility	NULL
,	NULL
called	NULL
complex	NULL
24	NULL
,	NULL
and	NULL
a	NULL
weaker	NULL
complex	NULL
with	NULL
a	NULL
higher	NULL
mobility	NULL
,	NULL
termed	NULL
2Â°	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
unlabeled	NULL
probe	NULL
effectively	NULL
competed	NULL
the	NULL
binding	NULL
of	NULL
both	NULL
complexes	NULL
(	NULL
Fig	NULL
4A	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Both	NULL
complexes	NULL
generated	NULL
with	NULL
this	NULL
probe	NULL
appeared	NULL
tissue	NULL
restricted	NULL
because	NULL
we	NULL
detected	NULL
them	NULL
in	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
different	NULL
B-cell	NULL
lines	NULL
but	NULL
not	NULL
from	NULL
T-cell	NULL
lines	NULL
or	NULL
HeLa	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
nucleotide	NULL
sequence	NULL
spanned	NULL
by	NULL
CD20	NULL
#	NULL
2	NULL
contains	NULL
an	NULL
AGAA	NULL
sequence	NULL
reminiscent	NULL
of	NULL
an	NULL
Ets	NULL
binding	NULL
site	NULL
,	NULL
although	NULL
this	NULL
does	NULL
not	NULL
match	NULL
the	NULL
Ets	NULL
consensus	NULL
sequence	NULL
.	NULL

Because	NULL
the	NULL
B-cell	NULL
and	NULL
macrophage-specific	NULL
Ets	NULL
family	NULL
member	NULL
PU.1	NULL
binds	NULL
a	NULL
purine	NULL
rich	NULL
sequence	NULL
containing	NULL
an	NULL
AGAA	NULL
sequence	NULL
in	NULL
the	NULL
J-chain	NULL
promoter	NULL
``	NULL
and	NULL
the	NULL
CD11b	NULL
promoter	NULL
,	NULL
``	NULL
we	NULL
tested	NULL
whether	NULL
or	NULL
not	NULL
PU.1	NULL
bound	NULL
site	NULL
2	NULL
.	NULL

We	NULL
found	NULL
that	NULL
an	NULL
SV40	NULL
PU.1	NULL
probe	NULL
``	NULL
efficiently	NULL
competed	NULL
the	NULL
formation	NULL
of	NULL
complexes	NULL
24	NULL
and	NULL
2	NULL
``	NULL
(	NULL
Fig	NULL
4A	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
6	NULL
)	NULL
,	NULL
and	NULL
conversely	NULL
,	NULL
the	NULL
CD20	NULL
#	NULL
2	NULL
probe	NULL
competed	NULL
the	NULL
binding	NULL
of	NULL
PU.1	NULL
to	NULL
the	NULL
SV40	NULL
PU.1	NULL
probe	NULL
(	NULL
Fig	NULL
4A	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
weaker	NULL
2Â°	NULL
complex	NULL
comigrated	NULL
with	NULL
the	NULL
band	NULL
generated	NULL
with	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3988	NULL
A	NULL
1Â°	NULL
2	NULL
03	NULL
4	NULL
B	NULL
1Â°	NULL
2	NULL
3	NULL
-180-	NULL
-180-re	NULL
<	NULL
:	NULL
-170-	NULL
MARR	NULL
A18586-	NULL
jSiteZ	NULL
-156-	NULL
jSiteZ	NULL
A43	NULL
-	NULL
Fa	NULL
1417-	NULL
we	NULL
ame	NULL
aan	NULL
138	NULL
--	NULL
138-	NULL
W	NULL
ws	NULL
126-114-	NULL
tim	NULL
114-pes	NULL
10s-	NULL
CR	NULL
i08g-	NULL
%	NULL
--	NULL
A	NULL
glee	NULL
%	NULL
%	NULL
a	NULL
t	NULL
&	NULL
.	NULL

Â©	NULL
e	NULL
o	NULL
4	NULL
%	NULL
*	NULL
9,9	NULL
3	NULL
*	NULL
>	NULL
Fig	NULL
2	NULL
.	NULL

In	NULL
vivo	NULL
footprinting	NULL
of	NULL
bases	NULL
-108	NULL
to	NULL
-180	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Naked	NULL
genomic	NULL
DNA	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
intact	NULL
cells	NULL
from	NULL
the	NULL
B-cell	NULL
line	NULL
HS-Sultan	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
T-cell	NULL
line	NULL
Jurkat	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
and	NULL
cervival	NULL
carcinoma	NULL
cell	NULL
line	NULL
HeLa	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
were	NULL
exposed	NULL
to	NULL
DMS	NULL
,	NULL
and	NULL
in	NULL
vivo	NULL
footprints	NULL
were	NULL
visualized	NULL
by	NULL
ligation	NULL
mediated	NULL
PCR	NULL
using	NULL
primer	NULL
set	NULL
3	NULL
.	NULL

The	NULL
numbers	NULL
on	NULL
the	NULL
left	NULL
correspond	NULL
to	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
shown	NULL
in	NULL
Fig	NULL
1D	NULL
.	NULL

The	NULL
protected	NULL
residues	NULL
were	NULL
designated	NULL
as	NULL
site	NULL
2	NULL
and	NULL
are	NULL
surrounded	NULL
by	NULL
a	NULL
bracket	NULL
.	NULL

(	NULL
B	NULL
)	NULL
In	NULL
vivo	NULL
footprinting	NULL
was	NULL
performed	NULL
in	NULL
an	NULL
identical	NULL
manner	NULL
using	NULL
the	NULL
following	NULL
cell	NULL
lines	NULL
:	NULL
lane	NULL
1	NULL
,	NULL
CD20-positive	NULL
plasmacytoma	NULL
cell	NULL
line	NULL
HS-Sultan	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
CD20-negative	NULL
pre-B-cell	NULL
line	NULL
PB697	NULL
;	NULL
and	NULL
lane	NULL
3	NULL
,	NULL
CD20-positive	NULL
B-cell	NULL
line	NULL
BJA-B	NULL
.	NULL

the	NULL
SV40	NULL
PU.1	NULL
probe	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
of	NULL
Fig	NULL
4A	NULL
)	NULL
,	NULL
the	NULL
stronger	NULL
24	NULL
complex	NULL
migrated	NULL
more	NULL
slowly	NULL
.	NULL

These	NULL
observations	NULL
indicated	NULL
that	NULL
the	NULL
CD20	NULL
#	NULL
2	NULL
probe	NULL
not	NULL
only	NULL
binds	NULL
PU.1	NULL
but	NULL
,	NULL
in	NULL
addition	NULL
,	NULL
another	NULL
protein	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
the	NULL
SV40	NULL
PU.1	NULL
probe	NULL
inhibited	NULL
formation	NULL
of	NULL
both	NULL
complexes	NULL
suggested	NULL
that	NULL
PU.1	NULL
was	NULL
required	NULL
for	NULL
detection	NULL
of	NULL
the	NULL
second	NULL
protein	NULL
.	NULL

To	NULL
address	NULL
this	NULL
possibility	NULL
we	NULL
immunoprecipitated	NULL
PU.1	NULL
from	NULL
a	NULL
B-cell	NULL
nuclear	NULL
extract	NULL
before	NULL
a	NULL
gel	NULL
shift	NULL
assay	NULL
with	NULL
the	NULL
CD20	NULL
#	NULL
2	NULL
probe	NULL
.	NULL

This	NULL
resulted	NULL
in	NULL
a	NULL
marked	NULL
reduction	NULL
in	NULL
the	NULL
2*	NULL
complex	NULL
and	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
2Â°	NULL
complex	NULL
(	NULL
Fig	NULL
4B	NULL
)	NULL
.	NULL

The	NULL
2Â°	NULL
complex	NULL
appears	NULL
to	NULL
be	NULL
composed	NULL
of	NULL
two	NULL
bands	NULL
,	NULL
one	NULL
that	NULL
vanished	NULL
with	NULL
the	NULL
PU.1	NULL
antibody	NULL
preclearance	NULL
and	NULL
another	NULL
that	NULL
did	NULL
not	NULL
.	NULL

The	NULL
failure	NULL
to	NULL
completely	NULL
reduce	NULL
the	NULL
2Â°	NULL
complex	NULL
may	NULL
result	NULL
from	NULL
incomplete	NULL
clearance	NULL
of	NULL
PU.1	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
another	NULL
DNA	NULL
binding	NULL
protein	NULL
in	NULL
the	NULL
complex	NULL
.	NULL

These	NULL
experiments	NULL
show	NULL
that	NULL
PU.1	NULL
and	NULL
PU.1	NULL
in	NULL
conjunction	NULL
with	NULL
another	NULL
protein	NULL
bind	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

Closer	NULL
inspection	NULL
of	NULL
the	NULL
sequence	NULL
surrounding	NULL
the	NULL
GA-rich	NULL
region	NULL
showed	NULL
that	NULL
the	NULL
nucleotide	NULL
sequence	NULL
of	NULL
probe	NULL
CD20	NULL
#	NULL
2	NULL
is	NULL
homologous	NULL
to	NULL
a	NULL
composite	NULL
binding	NULL
site	NULL
described	NULL
in	NULL
the	NULL
x3	NULL
'	NULL
enhancer	NULL
and	NULL
to	NULL
the	NULL
AB	NULL
element	NULL
of	NULL
the	NULL
A2	NULL
to	NULL
4	NULL
and	NULL
A3	NULL
to	NULL
1	NULL
enhancers	NULL
.	NULL

The	NULL
first	NULL
8	NULL
bp	NULL
after	NULL
the	NULL
GA-rich	NULL
region	NULL
are	NULL
identical	NULL
to	NULL
those	NULL
of	NULL
the	NULL
AB	NULL
element	NULL
and	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
the	NULL
x3	NULL
'	NULL
enhancer	NULL
(	NULL
6	NULL
of	NULL
8	NULL
match	NULL
)	NULL
.	NULL

The	NULL
protein	NULL
that	NULL
interacts	NULL
with	NULL
PU.1	NULL
at	NULL
these	NULL
sites	NULL
and	NULL
binds	NULL
to	NULL
the	NULL
conserved	NULL
sequence	NULL
immediately	NULL
3	NULL
'	NULL
of	NULL
HIMMELMANN	NULL
ET	NULL
AL	NULL
the	NULL
PU.1	NULL
binding	NULL
site	NULL
has	NULL
been	NULL
cloned	NULL
and	NULL
termed	NULL
Pip	NULL
for	NULL
PU.1	NULL
interacting	NULL
partner	NULL
.	NULL
``	NULL

''	NULL
Pip	NULL
expression	NULL
is	NULL
restricted	NULL
to	NULL
lymphocytes	NULL
with	NULL
higher	NULL
levels	NULL
in	NULL
B	NULL
cells	NULL
than	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Because	NULL
the	NULL
protein	NULL
interacting	NULL
with	NULL
PU.1	NULL
on	NULL
the	NULL
CD20	NULL
promoter	NULL
also	NULL
appeared	NULL
lymphocyte	NULL
restricted	NULL
,	NULL
Pip	NULL
was	NULL
an	NULL
attractive	NULL
candidate	NULL
for	NULL
the	NULL
additional	NULL
factor	NULL
.	NULL

PU.1	NULL
and	NULL
Pip	NULL
interact	NULL
to	NULL
bind	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
PU.1	NULL
and	NULL
Pip	NULL
could	NULL
bind	NULL
the	NULL
CD20	NULL
promoter	NULL
,	NULL
we	NULL
translated	NULL
both	NULL
proteins	NULL
in	NULL
vitro	NULL
and	NULL
used	NULL
them	NULL
in	NULL
an	NULL
EMSA	NULL
with	NULL
the	NULL
CD20	NULL
promoter	NULL
probe	NULL
20	NULL
#	NULL
2	NULL
.	NULL

The	NULL
in	NULL
vitro-translated	NULL
PU.1	NULL
bound	NULL
a	NULL
PU.1	NULL
probe	NULL
but	NULL
failed	NULL
to	NULL
bind	NULL
the	NULL
CD20	NULL
#	NULL
2	NULL
probe	NULL
(	NULL
Fig	NULL
5	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
7	NULL
)	NULL
.	NULL

We	NULL
observed	NULL
a	NULL
specific	NULL
complex	NULL
only	NULL
when	NULL
the	NULL
EMSA	NULL
reaction	NULL
contained	NULL
both	NULL
proteins	NULL
(	NULL
Fig	NULL
5	NULL
,	NULL
lanes	NULL
5	NULL
to	NULL
7	NULL
)	NULL
.	NULL

The	NULL
complex	NULL
had	NULL
a	NULL
slightly	NULL
different	NULL
mobility	NULL
compared	NULL
with	NULL
the	NULL
complex	NULL
generated	NULL
with	NULL
BJA-B	NULL
nuclear	NULL
extracts	NULL
(	NULL
complex	NULL
24	NULL
;	NULL
Fig	NULL
5	NULL
,	NULL
compare	NULL
lane	NULL
3	NULL
with	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

This	NULL
may	NULL
be	NULL
because	NULL
of	NULL
post-translational	NULL
modification	NULL
of	NULL
the	NULL
proteins	NULL
in	NULL
intact	NULL
cells	NULL
.	NULL

To	NULL
show	NULL
that	NULL
the	NULL
PU.1/Pip	NULL
interaction	NULL
on	NULL
the	NULL
CD20	NULL
promoter	NULL
probe	NULL
depended	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
Pip	NULL
to	NULL
the	NULL
sequence	NULL
3	NULL
'	NULL
of	NULL
the	NULL
GA-rich	NULL
PU.1	NULL
binding	NULL
site	NULL
,	NULL
we	NULL
introduced	NULL
a	NULL
mutation	NULL
into	NULL
the	NULL
Pip	NULL
binding	NULL
site	NULL
leaving	NULL
the	NULL
PU.1	NULL
binding	NULL
site	NULL
intact	NULL
.	NULL

No	NULL
complex	NULL
was	NULL
observed	NULL
when	NULL
this	NULL
probe	NULL
was	NULL
used	NULL
in	NULL
an	NULL
EMSA	NULL
along	NULL
with	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
and	NULL
Pip	NULL
(	NULL
Fig	NULL
5	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

We	NULL
next	NULL
compared	NULL
binding	NULL
of	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
to	NULL
the	NULL
CD20	NULL
#	NULL
2	NULL
probe	NULL
with	NULL
that	NULL
of	NULL
the	NULL
AB	NULL
element	NULL
.	NULL

Incubating	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
and	NULL
Pip	NULL
with	NULL
the	NULL
AB	NULL
probe	NULL
generated	NULL
a	NULL
complex	NULL
of	NULL
identical	NULL
mobility	NULL
(	NULL
Fig	NULL
5	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
12	NULL
)	NULL
.	NULL

As	NULL
we	NULL
had	NULL
observed	NULL
with	NULL
the	NULL
CD20	NULL
#	NULL
2	NULL
probe	NULL
,	NULL
the	NULL
complex	NULL
generated	NULL
with	NULL
nuclear	NULL
extracts	NULL
and	NULL
the	NULL
AB	NULL
probe	NULL
had	NULL
a	NULL
slightly	NULL
different	NULL
mobility	NULL
than	NULL
the	NULL
complex	NULL
generated	NULL
with	NULL
in	NULL
vitro	NULL
translated	NULL
proteins	NULL
(	NULL
Fig	NULL
5	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
12	NULL
)	NULL
.	NULL

The	NULL
two	NULL
elements	NULL
are	NULL
distinguished	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
AB	NULL
element	NULL
,	NULL
but	NULL
not	NULL
to	NULL
the	NULL
CD20	NULL
promoter	NULL
probe	NULL
(	NULL
Fig	NULL
5	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
11	NULL
)	NULL
.	NULL

To	NULL
verify	NULL
that	NULL
Pip	NULL
was	NULL
actually	NULL
a	NULL
component	NULL
of	NULL
complex	NULL
24	NULL
,	NULL
we	NULL
added	NULL
a	NULL
Pip-specific	NULL
antiserum	NULL
to	NULL
the	NULL
EMSA	NULL
reaction	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
normal	NULL
tonsil	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
the	NULL
Pip-specific	NULL
antiserum	NULL
,	NULL
but	NULL
not	NULL
a	NULL
control	NULL
antiserum	NULL
,	NULL
markedly	NULL
reduced	NULL
the	NULL
detection	NULL
of	NULL
the	NULL
complex	NULL
(	NULL
Fig	NULL
5	NULL
,	NULL
lanes	NULL
13	NULL
to	NULL
15	NULL
)	NULL
.	NULL

The	NULL
PU.1/Pip	NULL
complex	NULL
migrates	NULL
faster	NULL
than	NULL
a	NULL
nonspecific	NULL
band	NULL
that	NULL
we	NULL
commonly	NULL
detect	NULL
in	NULL
nuclear	NULL
extracts	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
these	NULL
experiments	NULL
identify	NULL
a	NULL
novel	NULL
composite	NULL
binding	NULL
site	NULL
for	NULL
PU.1	NULL
and	NULL
its	NULL
interaction	NULL
partner	NULL
Pip	NULL
on	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

Formation	NULL
of	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
depends	NULL
on	NULL
binding	NULL
of	NULL
both	NULL
PU.1	NULL
and	NULL
Pip	NULL
to	NULL
their	NULL
adjacent	NULL
binding	NULL
sites	NULL
with	NULL
Pip	NULL
apparently	NULL
stabilizing	NULL
the	NULL
binding	NULL
of	NULL
PU.1	NULL
to	NULL
a	NULL
GA-rich	NULL
sequence	NULL
that	NULL
lacks	NULL
an	NULL
Ets	NULL
consensus	NULL
sequence	NULL
.	NULL

CD20	NULL
expression	NULL
correlates	NULL
with	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
PU.1/	NULL
Pip	NULL
complex	NULL
during	NULL
B-cell	NULL
development	NULL
.	NULL

-	NULL
Because	NULL
the	NULL
PU.1/	NULL
Pip	NULL
complex	NULL
is	NULL
unique	NULL
to	NULL
B	NULL
cells	NULL
,	NULL
the	NULL
PU.1/Pip	NULL
site	NULL
in	NULL
the	NULL
CD20	NULL
promoter	NULL
may	NULL
account	NULL
for	NULL
the	NULL
lineage	NULL
specificity	NULL
of	NULL
the	NULL
CD20	NULL
gene	NULL
.	NULL

To	NULL
see	NULL
if	NULL
PU.1/Pip	NULL
expression	NULL
correlated	NULL
with	NULL
CD20	NULL
expression	NULL
during	NULL
B-cell	NULL
development	NULL
and	NULL
differentiation	NULL
,	NULL
we	NULL
examined	NULL
a	NULL
variety	NULL
of	NULL
B-cell	NULL
lines	NULL
for	NULL
CD20	NULL
and	NULL
PU.1/Pip	NULL
expression	NULL
.	NULL

The	NULL
pre-B-cell	NULL
lines	NULL
,	NULL
PB697	NULL
and	NULL
NALM-6	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
multiple	NULL
myeloma	NULL
cell	NULL
line	NULL
,	NULL
RPMI	NULL
8226	NULL
,	NULL
are	NULL
CD20	NULL
negative	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
these	NULL
cell	NULL
lines	NULL
were	NULL
prepared	NULL
and	NULL
examined	NULL
for	NULL
PU.1/Pip	NULL
via	NULL
EMSA	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

REGULATION	NULL
OF	NULL
CD20	NULL
PROMOTER	NULL
Fig	NULL
3	NULL
.	NULL

EMSA	NULL
shows	NULL
binding	NULL
of	NULL
basic	NULL
helix-loop-helix-zipper	NULL
transcription	NULL
factors	NULL
to	NULL
CD20	NULL
promoter	NULL
site	NULL
1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
A	NULL
total	NULL
of	NULL
0.5	NULL
ng	NULL
of	NULL
labeled	NULL
probe	NULL
CD20	NULL
#	NULL
1	NULL
{	NULL
lanes	NULL
1	NULL
to	NULL
5	NULL
)	NULL
or	NULL
a	NULL
E3	NULL
probe	NULL
(	NULL
6	NULL
to	NULL
9	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
BJA-B	NULL
nuclear	NULL
extracts	NULL
and	NULL
the	NULL
indicated	NULL
unlabeled	NULL
competitor	NULL
probe	NULL
(	NULL
200-fold	NULL
excess	NULL
)	NULL
.	NULL

The	NULL
resultant	NULL
complexes	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
5	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
same	NULL
probes	NULL
as	NULL
in	NULL
panel	NULL
A	NULL
were	NULL
either	NULL
incubated	NULL
with	NULL
in	NULL
vitro	NULL
translated	NULL
TFE3	NULL
{	NULL
lanes	NULL
1	NULL
to	NULL
8	NULL
)	NULL
or	NULL
BJA-B	NULL
nuclear	NULL
extracts	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
of	NULL
200-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
competitor	NULL
probe	NULL
.	NULL

In	NULL
vitro	NULL
translated	NULL
TFE3	NULL
was	NULL
either	NULL
incubated	NULL
with	NULL
preimmune	NULL
serum	NULL
{	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
)	NULL
or	NULL
anti-TFE3	NULL
antiserum	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
before	NULL
addition	NULL
of	NULL
the	NULL
indicated	NULL
probe	NULL
.	NULL

EMSA	NULL
was	NULL
performed	NULL
as	NULL
in	NULL
panel	NULL
A	NULL
.	NULL

(	NULL
C	NULL
)	NULL
USF1	NULL
is	NULL
a	NULL
major	NULL
component	NULL
of	NULL
complex	NULL
1	NULL
.	NULL

EMSA	NULL
in	NULL
which	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
indicated	NULL
source	NULL
have	NULL
been	NULL
preincubated	NULL
with	NULL
an	NULL
antiserum	NULL
to	NULL
USF1	NULL
or	NULL
USF2	NULL
or	NULL
with	NULL
preimmune	NULL
control	NULL
.	NULL

Competition	NULL
with	NULL
a	NULL
200-fold	NULL
excess	NULL
of	NULL
cold	NULL
probe	NULL
.	NULL

3989	NULL
A	NULL
1	NULL
2	NULL
3	NULL
4	NULL
50	NULL
6	NULL
7	NULL
8	NULL
9	NULL
u	NULL
.	NULL

v	NULL
'	NULL
.	NULL

-	NULL
Complex	NULL
1	NULL
|	NULL
Probe	NULL
CD20	NULL
#	NULL
1	NULL
uby	NULL
Competition	NULL
-_	NULL
WT	NULL
ue	NULL
,	NULL
uEgMul	NULL
-	NULL
WT	NULL
20	NULL
#	NULL
1	NULL
LE	NULL
;	NULL
&	NULL
3	NULL
B	NULL
@	NULL
TFE3	NULL
in	NULL
vitro	NULL
translated	NULL
Ã©	NULL
?	NULL

â	NULL
I	NULL
1	NULL
1Â°	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
~	NULL
-	NULL
Complex	NULL
1	NULL
U	NULL
B	NULL
=	NULL
aw	NULL
-TFE3	NULL
Probe	NULL
uEq	NULL
CD20	NULL
#	NULL
1	NULL
Competition	NULL
-o	NULL
owe	NULL
ome	NULL
&	NULL
e	NULL
ome	NULL
ook	NULL
k	NULL
ok	NULL
Anti-TFE3	NULL
&	NULL
-	NULL
-	NULL
e	NULL
e	NULL
e	NULL
g-pre-immune	NULL
-	NULL
sl	NULL
%	NULL
o	NULL
-l	NULL
so	NULL
so	NULL
#	NULL
i	NULL
=	NULL
)	NULL
i	NULL
>	NULL
C	NULL
BJA-B	NULL
N.E	NULL
.	NULL

HS-Sultan	NULL
N.E	NULL
.	NULL

I	NULL
1	NULL
I	NULL
1	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
Competition	NULL
Anti-USF1	NULL
Anti-USF2	NULL
Control	NULL
Antisera	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
PU.1-	NULL
.	NULL

Probe	NULL
PU	NULL
.	NULL

1	NULL
CD20	NULL
#	NULL
2	NULL
Competition	NULL
-	NULL
-	NULL
o	NULL
p	NULL
49	NULL
(	NULL
a	NULL
)	NULL
23	NULL
#	NULL
20	NULL
C3	NULL
ral	NULL
$	NULL
%	NULL
WH	NULL
Ws	NULL
-Complex	NULL
1	NULL
mo	NULL
gs	NULL
omas	NULL
as	NULL
oom	NULL
ao	NULL
pe	NULL
2	NULL
2	NULL
2	NULL
-	NULL
$	NULL
-	NULL
~	NULL
some	NULL
e	NULL
lms	NULL
um	NULL
S	NULL
isn	NULL
on	NULL
S6	NULL
ome	NULL
2	NULL
os	NULL
.P	NULL
mmo	NULL
Gm	NULL
oes	NULL
te	NULL
o	NULL
up	NULL
Co	NULL
C	NULL
OZ	NULL
L	NULL
g	NULL
B	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
C	NULL
I	NULL
-	NULL
>	NULL
725	NULL
BJA-B	NULL
N.E	NULL
.	NULL

+	NULL
+0	NULL
+0	NULL
+0	NULL
+	NULL
Competition	NULL
_	NULL
-	NULL
+	NULL
Co	NULL
z	NULL
z	NULL
Anti-PU.1	NULL
-	NULL
oe	NULL
p	NULL
~	NULL
Control	NULL
Ab	NULL
_	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-+	NULL
Fig	NULL
4	NULL
.	NULL

EMSA	NULL
shows	NULL
a	NULL
protein	NULL
complex	NULL
containing	NULL
PU.1	NULL
binds	NULL
CD20	NULL
promoter	NULL
site	NULL
2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSA	NULL
with	NULL
either	NULL
the	NULL
PU.1	NULL
site	NULL
of	NULL
the	NULL
SV-40	NULL
enhancer	NULL
(	NULL
PU.1	NULL
)	NULL
or	NULL
the	NULL
in	NULL
vivo	NULL
protected	NULL
site	NULL
2	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
(	NULL
CD20	NULL
#	NULL
2	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
BJA-B	NULL
nuclear	NULL
extract	NULL
and	NULL
the	NULL
indicated	NULL
unlabeled	NULL
competitor	NULL
probe	NULL
(	NULL
200-fold	NULL
excess	NULL
)	NULL
.	NULL

The	NULL
complexes	NULL
detected	NULL
with	NULL
the	NULL
CD20	NULL
#	NULL
2	NULL
probe	NULL
are	NULL
designated	NULL
complex	NULL
2*	NULL
and	NULL
2Â°	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSA	NULL
with	NULL
BJA-B	NULL
nuclear	NULL
extracts	NULL
depleted	NULL
of	NULL
PU.1	NULL
or	NULL
not	NULL
using	NULL
the	NULL
CD20	NULL
#	NULL
2	NULL
probe	NULL
.	NULL

As	NULL
in	NULL
panel	NULL
A	NULL
,	NULL
binding	NULL
was	NULL
competed	NULL
with	NULL
unlabeled	NULL
CD20	NULL
#	NULL
2	NULL
probe	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
SV-40	NULL
PU.1	NULL
probe	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

BJA-B	NULL
nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
rabbit	NULL
PU.1	NULL
antiserum	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
or	NULL
a	NULL
control	NULL
antiserum	NULL
{	NULL
lane	NULL
5	NULL
)	NULL
and	NULL
cleared	NULL
with	NULL
goat	NULL
antirabbit	NULL
Ig	NULL
coupled	NULL
to	NULL
magnetic	NULL
beads	NULL
before	NULL
the	NULL
EMSA	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3990	NULL
HIMMELMANN	NULL
ET	NULL
AL	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
-PU.1/Pip	NULL
i=	NULL
w	NULL
lund	NULL
'	NULL
'	NULL
to	NULL
Sad	NULL
-PU.1	NULL
(	NULL
Wns	NULL
L	NULL
II	NULL
|	NULL
*	NULL
|	NULL
I	NULL
l	NULL
|	NULL
Probe	NULL
__	NULL
PU	NULL
.	NULL

1	NULL
CD20	NULL
#	NULL
2	NULL
Â®	NULL
1B	NULL
CD20	NULL
#	NULL
2	NULL
*	NULL
Competition	NULL
Se	NULL
e	NULL
eae	NULL
N.E	NULL
.	NULL

-	NULL
&	NULL
op	NULL
p	NULL
-e	NULL
--	NULL
-	NULL
+	NULL
go-	NULL
-	NULL
+	NULL
+o	NULL
+o	NULL
+	NULL
PU.1	NULL
4	NULL
$	NULL
0oms	NULL
m	NULL
ots	NULL
ts	NULL
oto	NULL
ocho	NULL
-l	NULL
u	NULL
os	NULL
+	NULL
-	NULL
-	NULL
-	NULL
Pip	NULL
_i	NULL
o	NULL
ts	NULL
dap	NULL
Ip	NULL
(	NULL
et	NULL
sen	NULL
aft	NULL
o	NULL
Kad	NULL
|	NULL
man	NULL
0	NULL
<	NULL
fap	NULL
me	NULL
-	NULL
iad	NULL
|	NULL
kee	NULL
|	NULL
ces	NULL
Lysate	NULL
&	NULL
e	NULL
e	NULL
e	NULL
e	NULL
ape	NULL
e	NULL
o	NULL
p	NULL
o	NULL
o	NULL
<	NULL
-	NULL
--	NULL
Anti-Pip	NULL
=	NULL
#	NULL
-i	NULL
G	NULL
wok	NULL
)	NULL
q	NULL
;	NULL
ai	NULL
iio	NULL
A	NULL
[	NULL
l	NULL
is	NULL
)	NULL
TS	NULL
e	NULL
0	NULL
p	NULL
Preimmune	NULL
-_	NULL
we	NULL
Ln	NULL
is	NULL
tan	NULL
anl	NULL
HB	NULL
=	NULL
tert	NULL
|	NULL
mee	NULL
-	NULL
is	NULL
=-	NULL
=~	NULL
-	NULL
+	NULL
Fig	NULL
5	NULL
.	NULL

PU.1	NULL
and	NULL
Pip	NULL
bind	NULL
cooperatively	NULL
to	NULL
the	NULL
CD20	NULL
promoter	NULL
and	NULL
the	NULL
AB	NULL
element	NULL
.	NULL

A	NULL
total	NULL
of	NULL
0.5	NULL
ng	NULL
of	NULL
the	NULL
indicated	NULL
labeled	NULL
probe	NULL
were	NULL
incubated	NULL
either	NULL
with	NULL
BJA-B	NULL
nuclear	NULL
extract	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
9	NULL
,	NULL
and	NULL
10	NULL
)	NULL
,	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
a	NULL
combination	NULL
of	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
and	NULL
either	NULL
in	NULL
vitro	NULL
translated	NULL
Pip	NULL
(	NULL
lanes	NULL
5	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
and	NULL
12	NULL
)	NULL
,	NULL
unprogrammed	NULL
reticulocyte	NULL
lysate	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
11	NULL
)	NULL
,	NULL
or	NULL
a	NULL
tonsil	NULL
B	NULL
nuclear	NULL
extract	NULL
{	NULL
lanes	NULL
13	NULL
to	NULL
16	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
preimmune	NULL
antisera	NULL
(	NULL
lane	NULL
15	NULL
)	NULL
or	NULL
anti-Pip	NULL
antiserum	NULL
(	NULL
lane	NULL
16	NULL
)	NULL
.	NULL

The	NULL
PU.1/Pip	NULL
complex	NULL
migrates	NULL
slightly	NULL
faster	NULL
than	NULL
a	NULL
nonspecific	NULL
complex	NULL
that	NULL
can	NULL
be	NULL
partially	NULL
competed	NULL
by	NULL
any	NULL
DNA	NULL
probe	NULL
.	NULL

A	NULL
200-fold	NULL
excess	NULL
of	NULL
respective	NULL
unlabeled	NULL
competitor	NULL
probe	NULL
was	NULL
added	NULL
in	NULL
the	NULL
indicated	NULL
lanes	NULL
(	NULL
+	NULL
)	NULL
.	NULL

EMSA	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
3	NULL
.	NULL

Lanes	NULL
1	NULL
to	NULL
8	NULL
,	NULL
lanes	NULL
9	NULL
to	NULL
12	NULL
,	NULL
and	NULL
lanes	NULL
13	NULL
to	NULL
16	NULL
are	NULL
from	NULL
three	NULL
separate	NULL
experiments	NULL
so	NULL
the	NULL
migration	NULL
of	NULL
PU.1	NULL
and	NULL
PU.1/Pip	NULL
are	NULL
slightly	NULL
different	NULL
.	NULL

using	NULL
the	NULL
CD20	NULL
#	NULL
2	NULL
probe	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
6	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
could	NULL
not	NULL
be	NULL
detected	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
EMSA	NULL
in	NULL
them	NULL
(	NULL
Fig	NULL
6	NULL
,	NULL
lanes	NULL
2	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
was	NULL
found	NULL
to	NULL
be	NULL
present	NULL
in	NULL
all	NULL
CD20-positive	NULL
cell	NULL
lines	NULL
tested	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
next	NULL
wanted	NULL
to	NULL
know	NULL
which	NULL
partner	NULL
of	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
was	NULL
absent	NULL
or	NULL
functionally	NULL
impaired	NULL
in	NULL
the	NULL
CD20-negative	NULL
cell	NULL
lines	NULL
.	NULL

We	NULL
approached	NULL
this	NULL
by	NULL
adding	NULL
either	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
or	NULL
Pip	NULL
to	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
CD20-negative	NULL
cell	NULL
lines	NULL
.	NULL

Addition	NULL
of	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
reconstituted	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
in	NULL
the	NULL
PB697	NULL
,	NULL
NALM-6	NULL
,	NULL
and	NULL
RPMI	NULL
8226	NULL
nuclear	NULL
extracts	NULL
whereas	NULL
addition	NULL
of	NULL
Pip	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Fig	NULL
6A	NULL
,	NULL
Lanes	NULL
2,3,5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
8	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
in	NULL
these	NULL
three	NULL
CD20-negative	NULL
cell	NULL
lines	NULL
is	NULL
because	NULL
of	NULL
low	NULL
levels	NULL
of	NULL
PU.1	NULL
or	NULL
a	NULL
functional	NULL
impairment	NULL
of	NULL
PU.1	NULL
that	NULL
prevents	NULL
it	NULL
from	NULL
interacting	NULL
with	NULL
Pip	NULL
.	NULL

Analysis	NULL
of	NULL
PU.1	NULL
protein	NULL
expression	NULL
in	NULL
CD2O0-negative	NULL
and	NULL
-positive	NULL
B-cell	NULL
lines	NULL
.	NULL

-	NULL
As	NULL
a	NULL
first	NULL
approach	NULL
to	NULL
distinguish	NULL
the	NULL
above	NULL
mentioned	NULL
possibilities	NULL
,	NULL
we	NULL
determined	NULL
PU.1	NULL
protein	NULL
levels	NULL
in	NULL
the	NULL
various	NULL
CD20-negative	NULL
and	NULL
-positive	NULL
B-cell	NULL
lines	NULL
.	NULL

Both	NULL
PB697	NULL
cells	NULL
and	NULL
RPMI	NULL
8226	NULL
lacked	NULL
PU.1	NULL
by	NULL
EMSA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
;	NULL
however	NULL
,	NULL
NALM-6	NULL
contained	NULL
levels	NULL
comparable	NULL
with	NULL
mature	NULL
B	NULL
cells	NULL
(	NULL
Fig	NULL
6A	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

We	NULL
also	NULL
checked	NULL
PU.1	NULL
levels	NULL
by	NULL
immunoblotting	NULL
cellular	NULL
extracts	NULL
.	NULL

As	NULL
a	NULL
positive	NULL
control	NULL
we	NULL
used	NULL
S-labeled	NULL
PU.1	NULL
,	NULL
in	NULL
vitro	NULL
transcribed	NULL
and	NULL
translated	NULL
from	NULL
a	NULL
mouse	NULL
cDNA	NULL
.	NULL

Identical	NULL
bands	NULL
(	NULL
a	NULL
major	NULL
band	NULL
and	NULL
a	NULL
minor	NULL
band	NULL
of	NULL
slower	NULL
mobility	NULL
)	NULL
were	NULL
visualized	NULL
by	NULL
immunodetection	NULL
with	NULL
the	NULL
PU.1	NULL
antiserum	NULL
(	NULL
Fig	NULL
6B	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
or	NULL
by	NULL
autoradiography	NULL
of	NULL
the	NULL
same	NULL
membrane	NULL
(	NULL
Fig	NULL
6B	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
gel	NULL
shift	NULL
results	NULL
,	NULL
PU.1	NULL
levels	NULL
were	NULL
low	NULL
or	NULL
undetectable	NULL
in	NULL
RPMI	NULL
8226	NULL
,	NULL
PB697	NULL
,	NULL
and	NULL
in	NULL
addition	NULL
,	NULL
Jurkat	NULL
and	NULL
K562	NULL
(	NULL
Fig	NULL
6B	NULL
,	NULL
lanes	NULL
4	NULL
to	NULL
7	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
lysates	NULL
from	NULL
NALM-6	NULL
cells	NULL
contained	NULL
nearly	NULL
equivalent	NULL
levels	NULL
of	NULL
PU.1	NULL
to	NULL
those	NULL
found	NULL
in	NULL
the	NULL
mature	NULL
B-cell	NULL
lines	NULL
HS-Sultan	NULL
and	NULL
SuDHL4	NULL
(	NULL
Fig	NULL
6B	NULL
,	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
the	NULL
NALM-6	NULL
cells	NULL
lacked	NULL
several	NULL
minor	NULL
bands	NULL
detected	NULL
in	NULL
the	NULL
mature	NULL
B	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
explain	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
in	NULL
PB697	NULL
and	NULL
RPMI	NULL
8226	NULL
cells	NULL
and	NULL
raise	NULL
the	NULL
possibility	NULL
that	NULL
PU.1	NULL
is	NULL
unable	NULL
to	NULL
interact	NULL
with	NULL
Pip	NULL
in	NULL
NALM-6	NULL
cells	NULL
.	NULL

Functional	NULL
analysis	NULL
of	NULL
the	NULL
PU.1/Pip	NULL
and	NULL
the	NULL
uE3	NULL
binding	NULL
sites	NULL
.	NULL

-	NULL
To	NULL
define	NULL
the	NULL
functional	NULL
significance	NULL
of	NULL
the	NULL
PU.1/Pip	NULL
site	NULL
and	NULL
the	NULL
E3	NULL
element	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
,	NULL
we	NULL
transiently	NULL
transfected	NULL
various	NULL
cell	NULL
lines	NULL
with	NULL
wild	NULL
type	NULL
and	NULL
mutant	NULL
C20	NULL
promoter	NULL
constructs	NULL
.	NULL

The	NULL
wild-type	NULL
reporter	NULL
construct	NULL
consisted	NULL
of	NULL
the	NULL
first	NULL
425	NULL
bp	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
(	NULL
CD20-425	NULL
WT	NULL
)	NULL
placed	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
luciferase	NULL
gene	NULL
.	NULL

This	NULL
construct	NULL
is	NULL
very	NULL
active	NULL
in	NULL
the	NULL
CD20-positive	NULL
B-cell	NULL
line	NULL
HS-Sultan	NULL
but	NULL
considerably	NULL
less	NULL
so	NULL
in	NULL
the	NULL
T-cell	NULL
line	NULL
,	NULL
Jurkat	NULL
,	NULL
and	NULL
in	NULL
the	NULL
CD20-negative	NULL
myeloma	NULL
cell	NULL
lines	NULL
,	NULL
U266	NULL
and	NULL
RPMI-8226	NULL
(	NULL
Fig	NULL
7	NULL
)	NULL
.	NULL

Mutations	NULL
were	NULL
introduced	NULL
into	NULL
the	NULL
PU.1/Pip	NULL
binding	NULL
site	NULL
or	NULL
into	NULL
the	NULL
wE3	NULL
element	NULL
of	NULL
the	NULL
CD20-425	NULL
WT	NULL
construct	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
that	NULL
resulted	NULL
in	NULL
the	NULL
loss	NULL
of	NULL
binding	NULL
of	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
or	NULL
of	NULL
bHLHZ	NULL
proteins	NULL
to	NULL
their	NULL
respective	NULL
binding	NULL
sites	NULL
as	NULL
assessed	NULL
by	NULL
EMSA	NULL
.	NULL

To	NULL
normalize	NULL
for	NULL
differences	NULL
in	NULL
transfection	NULL
efficiency	NULL
a	NULL
3-Gal	NULL
control	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
.	NULL

A	NULL
mutation	NULL
that	NULL
abolished	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
reduced	NULL
CD20	NULL
promoter	NULL
activity	NULL
in	NULL
HS-Sultan	NULL
cells	NULL
nearly	NULL
to	NULL
background	NULL
levels	NULL
(	NULL
14-fold	NULL
reduction	NULL
;	NULL
Fig	NULL
7	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
mutation	NULL
failed	NULL
to	NULL
alter	NULL
the	NULL
low	NULL
levels	NULL
of	NULL
promoter	NULL
activity	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

A	NULL
mutation	NULL
in	NULL
the	NULL
E3	NULL
binding	NULL
site	NULL
had	NULL
a	NULL
mild	NULL
effect	NULL
on	NULL
the	NULL
promoter	NULL
activity	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
2-fold	NULL
reduc-tion	NULL
)	NULL
but	NULL
dramatically	NULL
reduced	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
promoter	NULL
construct	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
show	NULL
a	NULL
requirement	NULL
for	NULL
an	NULL
intact	NULL
PU.1/Pip	NULL
binding	NULL
site	NULL
for	NULL
CD20	NULL
promoter	NULL
function	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

Although	NULL
the	NULL
E3	NULL
site	NULL
is	NULL
less	NULL
critical	NULL
,	NULL
it	NULL
can	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

REGULATION	NULL
OF	NULL
CD20	NULL
PROMOTER	NULL
1	NULL
le	NULL
coal	NULL
N.E	NULL
.	NULL

PU.1	NULL
__+	NULL
Pip	NULL
+	NULL
kDa	NULL
_	NULL
1	NULL
Fig	NULL
6	NULL
.	NULL

-	NULL
Absence	NULL
of	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
in	NULL
â¬D20-	NULL
-	NULL
49	NULL
negative	NULL
cell	NULL
lines	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSA	NULL
was	NULL
performed	NULL
with	NULL
0.5	NULL
ng	NULL
of	NULL
the	NULL
CD20	NULL
#	NULL
2	NULL
probe	NULL
or	NULL
the	NULL
SV40	NULL
PU.1	NULL
probe	NULL
{	NULL
lane	NULL
9	NULL
)	NULL
and	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
and	NULL
Pip	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
nuclear	NULL
extracts	NULL
from	NULL
B-cell	NULL
lines	NULL
PB697	NULL
(	NULL
lanes	NULL
2,3	NULL
,	NULL
and	NULL
4	NULL
)	NULL
,	NULL
RPMI	NULL
8226	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
or	NULL
NALM-6	NULL
.	NULL

In	NULL
vitro	NULL
translated	NULL
proteins	NULL
were	NULL
added	NULL
to	NULL
the	NULL
gel	NULL
shift	NULL
37	NULL
reactions	NULL
as	NULL
indicated	NULL
.	NULL

NS	NULL
denotes	NULL
a	NULL
nonspecific	NULL
band	NULL
.	NULL

(	NULL
B	NULL
)	NULL
PU.1	NULL
immunoblot	NULL
.	NULL

A	NULL
total	NULL
of	NULL
100	NULL
ag	NULL
of	NULL
whole	NULL
cell	NULL
lysate	NULL
of	NULL
the	NULL
indicated	NULL
cell	NULL
line	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
7	NULL
)	NULL
or	NULL
6	NULL
\	NULL
of	NULL
``	NULL
S-labeled	NULL
in	NULL
vitro	NULL
translated	NULL
mouse	NULL
PU.1	NULL
{	NULL
lane	NULL
8	NULL
)	NULL
were	NULL
fractionated	NULL
by	NULL
SDS-PAGE	NULL
and	NULL
immu-noblotted	NULL
with	NULL
a	NULL
rabbit	NULL
PU.1	NULL
antiserum	NULL
.	NULL

Autoradiography	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
same	NULL
membrane	NULL
to	NULL
verify	NULL
the	NULL
position	NULL
of	NULL
``	NULL
S-labeled	NULL
PU.1	NULL
(	NULL
lane	NULL
9	NULL
}	NULL
.	NULL

significantly	NULL
contribute	NULL
to	NULL
CD20	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
E3	NULL
site	NULL
in	NULL
the	NULL
promoter	NULL
is	NULL
largely	NULL
responsible	NULL
for	NULL
the	NULL
low	NULL
activity	NULL
of	NULL
the	NULL
promoter	NULL
construct	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

-	NULL
The	NULL
previous	NULL
experiments	NULL
had	NULL
shown	NULL
the	NULL
binding	NULL
of	NULL
PU.1/Pip	NULL
,	NULL
TFE3	NULL
,	NULL
and	NULL
USF	NULL
to	NULL
two	NULL
different	NULL
elements	NULL
in	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

The	NULL
interaction	NULL
of	NULL
Oct-2	NULL
with	NULL
the	NULL
CD20	NULL
promoter	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
.	NULL
'	NULL

''	NULL
We	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
PU.1	NULL
,	NULL
Pip	NULL
,	NULL
TFE3	NULL
,	NULL
USF	NULL
,	NULL
and	NULL
Oct-2	NULL
to	NULL
transactivate	NULL
the	NULL
CD20	NULL
promoter	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
various	NULL
combinations	NULL
.	NULL

We	NULL
cotransfected	NULL
the	NULL
CD20-425	NULL
WT	NULL
construct	NULL
and	NULL
various	NULL
expression	NULL
vectors	NULL
into	NULL
the	NULL
fibroblast	NULL
cell	NULL
line	NULL
NIH3T3	NULL
that	NULL
lacks	NULL
PU.1	NULL
,	NULL
Pip	NULL
,	NULL
and	NULL
Oct-2	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
overexpression	NULL
of	NULL
TFE3	NULL
or	NULL
USF	NULL
in	NULL
these	NULL
cells	NULL
can	NULL
transactivate	NULL
reporter	NULL
constructs	NULL
that	NULL
have	NULL
functional	NULL
binding	NULL
sites	NULL
for	NULL
these	NULL
proteins	NULL
despite	NULL
endogenous	NULL
levels	NULL
in	NULL
NIH3T3	NULL
cells	NULL
.	NULL

A	NULL
3-Gal	NULL
control	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
to	NULL
normalize	NULL
for	NULL
differences	NULL
in	NULL
transfection	NULL
efficiency	NULL
,	NULL
and	NULL
various	NULL
amounts	NULL
of	NULL
an	NULL
empty	NULL
expression	NULL
vector	NULL
were	NULL
added	NULL
to	NULL
keep	NULL
the	NULL
amount	NULL
of	NULL
transfected	NULL
DNA	NULL
constant	NULL
.	NULL

Control	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
reporter	NULL
constructs	NULL
containing	NULL
mutations	NULL
in	NULL
either	NULL
the	NULL
3991	NULL
pesar	NULL
-	NULL
B5M	NULL
-	NULL
nam-s	NULL
}	NULL
I	NULL
1	NULL
203	NULL
40	NULL
5	NULL
60	NULL
7	NULL
s	NULL
9	NULL
tas	NULL
tus	NULL
mas	NULL
gus	NULL
<	NULL
-ns	NULL
-	NULL
PU	NULL
.	NULL

1/Pip	NULL
U	NULL
-	NULL
PU	NULL
.	NULL

1	NULL
Â®	NULL
Uo	NULL
-=	NULL
G	NULL
-	NULL
G	NULL
%	NULL
%	NULL
%	NULL
%	NULL
G	NULL
%	NULL
Â¢	NULL
?	NULL

Â¢2Qz	NULL
st	NULL
nt	NULL
at	NULL
*	NULL
%	NULL
?	NULL

%	NULL
b	NULL
x2	NULL
>	NULL
&	NULL
PU.1/Pip	NULL
or	NULL
the	NULL
wE3	NULL
site	NULL
.	NULL

The	NULL
results	NULL
of	NULL
these	NULL
experiments	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

As	NULL
expected	NULL
neither	NULL
PU.1	NULL
nor	NULL
Pip	NULL
transactivated	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

The	NULL
simultaneous	NULL
expression	NULL
of	NULL
PU.1	NULL
and	NULL
Pip	NULL
in	NULL
3T3	NULL
cells	NULL
resulted	NULL
in	NULL
a	NULL
low	NULL
but	NULL
reproducible	NULL
2.3-fold	NULL
increase	NULL
in	NULL
reporter	NULL
gene	NULL
activity	NULL
.	NULL

We	NULL
observed	NULL
similar	NULL
levels	NULL
of	NULL
transactivation	NULL
when	NULL
either	NULL
Oct-2	NULL
or	NULL
TFE3	NULL
were	NULL
cotransfected	NULL
(	NULL
2-	NULL
to	NULL
2.2-fold	NULL
induction	NULL
)	NULL
.	NULL

The	NULL
transcription	NULL
factor	NULL
USF	NULL
was	NULL
found	NULL
to	NULL
be	NULL
a	NULL
potent	NULL
transacti-vator	NULL
of	NULL
the	NULL
CD20	NULL
gene	NULL
promoter	NULL
,	NULL
a	NULL
6-	NULL
to	NULL
7-fold	NULL
induction	NULL
of	NULL
reporter	NULL
gene	NULL
activity	NULL
was	NULL
consistently	NULL
observed	NULL
.	NULL

In	NULL
cotransfection	NULL
experiments	NULL
using	NULL
the	NULL
respective	NULL
mutated	NULL
promoter-reporter	NULL
constructs	NULL
a	NULL
minimal	NULL
(	NULL
1.6-fold	NULL
)	NULL
transactivation	NULL
by	NULL
USF	NULL
could	NULL
be	NULL
observed	NULL
.	NULL

This	NULL
may	NULL
indicate	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
additional	NULL
functional	NULL
E3	NULL
binding	NULL
site	NULL
.	NULL

We	NULL
next	NULL
tested	NULL
whether	NULL
the	NULL
various	NULL
transcription	NULL
factors	NULL
that	NULL
transactivated	NULL
the	NULL
CD20	NULL
promoter	NULL
could	NULL
cooperate	NULL
in	NULL
this	NULL
function	NULL
.	NULL

Coexpression	NULL
of	NULL
PU.1/Pip	NULL
and	NULL
Oct-2	NULL
in	NULL
3T3	NULL
cells	NULL
resulted	NULL
in	NULL
a	NULL
4.4-fold	NULL
increase	NULL
in	NULL
reporter	NULL
gene	NULL
activity	NULL
,	NULL
which	NULL
corresponds	NULL
to	NULL
the	NULL
sum	NULL
of	NULL
activation	NULL
by	NULL
PU.1/Pip	NULL
or	NULL
Oct-2	NULL
alone	NULL
.	NULL

Likewise	NULL
,	NULL
cotransfection	NULL
of	NULL
PU.1/Pip	NULL
and	NULL
TFE3	NULL
led	NULL
to	NULL
a	NULL
transactivation	NULL
of	NULL
the	NULL
reporter	NULL
gene	NULL
by	NULL
4-fold	NULL
,	NULL
which	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3992	NULL
HIMMELMANN	NULL
ET	NULL
AL	NULL
15	NULL
,	NULL
1.5p	NULL
Lu	NULL
CI	NULL
pGL3basic	NULL
U	NULL
E3	NULL
CD20-425-WT	NULL
<	NULL
4	NULL
CD20-425-uE3Mut	NULL
CC	NULL
a	NULL
CD20-425-PU.1/PipMut	NULL
LL	NULL
iy	NULL
10	NULL
oE	NULL
32	NULL
W	NULL
Q	NULL
24	NULL
5	NULL
'	NULL
_	NULL
<	NULL
T	NULL
_	NULL
]	NULL
LL	NULL
CC	NULL
O	NULL
HS-Sultan	NULL
U266	NULL
-	NULL
RPMI-	NULL
Jurkat	NULL
8226	NULL
Fig	NULL
7	NULL
.	NULL

-	NULL
Effect	NULL
of	NULL
mutations	NULL
in	NULL
the	NULL
PU.1/Pip	NULL
or	NULL
gE3	NULL
site	NULL
on	NULL
CD20	NULL
promoter	NULL
activity	NULL
in	NULL
B	NULL
cells	NULL
or	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
promoterless	NULL
luciferase	NULL
vector	NULL
pGL3	NULL
basic	NULL
,	NULL
the	NULL
wild-type	NULL
CD20	NULL
promoter-luciferase	NULL
gene	NULL
construct	NULL
(	NULL
CD20-425-WT	NULL
)	NULL
,	NULL
the	NULL
site	NULL
mutated	NULL
construct	NULL
(	NULL
CD20-425-zE3	NULL
Mut	NULL
:	NULL
CACCTG	NULL
-	NULL
>	NULL
AGCCGA	NULL
)	NULL
and	NULL
the	NULL
PU.1/Pip	NULL
site-mutated	NULL
construct	NULL
(	NULL
CD20-425-PU.1/Pip	NULL
Mut	NULL
:	NULL
AAGAAGT	NULL
-	NULL
ACTCCGT	NULL
)	NULL
were	NULL
transiently	NULL
transfected	NULL
into	NULL
the	NULL
B-cell	NULL
lines	NULL
,	NULL
HS-Sultan	NULL
,	NULL
U266	NULL
,	NULL
and	NULL
RPMI	NULL
8226	NULL
,	NULL
or	NULL
the	NULL
T-cell	NULL
line	NULL
,	NULL
Jurkat	NULL
.	NULL

Experiments	NULL
were	NULL
performed	NULL
in	NULL
triplicates	NULL
and	NULL
repeated	NULL
a	NULL
minimum	NULL
of	NULL
three	NULL
times	NULL
.	NULL

Mean	NULL
and	NULL
standard	NULL
deviation	NULL
values	NULL
shown	NULL
are	NULL
derived	NULL
from	NULL
a	NULL
representative	NULL
experiment	NULL
.	NULL

Luciferase	NULL
activities	NULL
were	NULL
normalized	NULL
for	NULL
transfection	NULL
efficiency	NULL
by	NULL
cotransfection	NULL
of	NULL
a	NULL
control	NULL
plasmid	NULL
.	NULL

Note	NULL
the	NULL
different	NULL
scales	NULL
used	NULL
for	NULL
the	NULL
B-cell	NULL
lines	NULL
and	NULL
Jurkat	NULL
cells	NULL
.	NULL

again	NULL
indicates	NULL
an	NULL
additive	NULL
effect	NULL
.	NULL

Transactivation	NULL
by	NULL
USF	NULL
could	NULL
be	NULL
further	NULL
increased	NULL
by	NULL
coexpressing	NULL
USF	NULL
along	NULL
with	NULL
Oct-2	NULL
(	NULL
up	NULL
to	NULL
9.3-fold	NULL
)	NULL
but	NULL
not	NULL
by	NULL
cotransfecting	NULL
USF	NULL
along	NULL
with	NULL
PU.1	NULL
and	NULL
Pip	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
these	NULL
experiments	NULL
show	NULL
that	NULL
the	NULL
CD20	NULL
promoter	NULL
can	NULL
be	NULL
transactivated	NULL
in	NULL
an	NULL
additive	NULL
fashion	NULL
by	NULL
the	NULL
B-cell-specific	NULL
factors	NULL
Oct-2	NULL
and	NULL
PU.1/Pip	NULL
,	NULL
but	NULL
no	NULL
evidence	NULL
of	NULL
a	NULL
functional	NULL
synergy	NULL
was	NULL
found	NULL
(	NULL
except	NULL
for	NULL
the	NULL
PU.1/Pip	NULL
cooperation	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
ubiquitous	NULL
factor	NULL
USF	NULL
was	NULL
the	NULL
strongest	NULL
activator	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

Table	NULL
1	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
CD20	NULL
Gene	NULL
Promoter	NULL
Induction	NULL
of	NULL
Mutated	NULL
Transcription	NULL
Factor	NULL
(	NULL
s	NULL
}	NULL
Induction	NULL
Wild	NULL
Type*	NULL
Constructt	NULL
PU.1	NULL
1	NULL
1	NULL
Pip	NULL
1	NULL
1	NULL
PU.1	NULL
+	NULL
Pip	NULL
2.3	NULL
1	NULL
Oct-2	NULL
2.2	NULL
NT	NULL
TFE3	NULL
2	NULL
1	NULL
USF	NULL
6.5	NULL
1.6	NULL
PU.1	NULL
+	NULL
Pip	NULL
+	NULL
Oct-2	NULL
4.4	NULL
NT	NULL
PU.1	NULL
+	NULL
Pip	NULL
+	NULL
TFE3	NULL
4	NULL
NT	NULL
PU.1	NULL
+	NULL
Pip	NULL
+	NULL
USF	NULL
6.5	NULL
NT	NULL
USF	NULL
+	NULL
Oct-2	NULL
9.3	NULL
NT	NULL
A	NULL
total	NULL
of	NULL
6	NULL
ug	NULL
of	NULL
construct	NULL
pGL3-CD20-425	NULL
were	NULL
transiently	NULL
cotransfected	NULL
with	NULL
2.5	NULL
ug	NULL
of	NULL
each	NULL
indicated	NULL
expression	NULL
vector	NULL
into	NULL
NIH-3T3	NULL
fibroblasts	NULL
.	NULL

The	NULL
total	NULL
amount	NULL
of	NULL
transfected	NULL
DNA	NULL
was	NULL
kept	NULL
constant	NULL
with	NULL
empty	NULL
expression	NULL
vector	NULL
pC-CMV	NULL
and	NULL
a	NULL
control	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
to	NULL
normalize	NULL
for	NULL
transfection	NULL
efficiency	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
and	NULL
luciferase	NULL
assay	NULL
performed	NULL
after	NULL
16	NULL
hours	NULL
.	NULL

*	NULL
The	NULL
Luciferase	NULL
Activity	NULL
of	NULL
the	NULL
reporter	NULL
construct	NULL
alone	NULL
has	NULL
been	NULL
set	NULL
at	NULL
1.0	NULL
.	NULL

Induction	NULL
refers	NULL
to	NULL
fold	NULL
increase	NULL
of	NULL
luciferase	NULL
activity	NULL
observed	NULL
with	NULL
cotransfection	NULL
.	NULL

Results	NULL
reported	NULL
are	NULL
an	NULL
average	NULL
of	NULL
3	NULL
to	NULL
5	NULL
independent	NULL
transfections	NULL
.	NULL

t	NULL
For	NULL
control	NULL
experiments	NULL
a	NULL
promoter-reporter	NULL
construct	NULL
with	NULL
a	NULL
mutation	NULL
of	NULL
the	NULL
PU.1/Pip	NULL
or	NULL
E3	NULL
binding	NULL
site	NULL
was	NULL
used	NULL
.	NULL

DISCUSSION	NULL
We	NULL
report	NULL
the	NULL
identification	NULL
of	NULL
two	NULL
cis-acting	NULL
elements	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
CD20	NULL
gene	NULL
that	NULL
are	NULL
important	NULL
for	NULL
the	NULL
tissue-specific	NULL
activity	NULL
of	NULL
this	NULL
promoter	NULL
.	NULL

One	NULL
element	NULL
is	NULL
homologous	NULL
to	NULL
a	NULL
DNA	NULL
element	NULL
in	NULL
the	NULL
Ig	NULL
x	NULL
3	NULL
'	NULL
enhancer	NULL
and	NULL
the	NULL
AB	NULL
motif	NULL
described	NULL
in	NULL
the	NULL
Ig	NULL
A	NULL
enhancers	NULL
;	NULL
although	NULL
in	NULL
contrast	NULL
to	NULL
these	NULL
sites	NULL
the	NULL
CD20	NULL
promoter	NULL
site	NULL
lacks	NULL
a	NULL
consensus	NULL
Ets	NULL
sequence	NULL
.	NULL

Analogous	NULL
to	NULL
these	NULL
elements	NULL
a	NULL
B-cell-specific	NULL
ternary	NULL
complex	NULL
forms	NULL
on	NULL
the	NULL
CD20	NULL
promoter	NULL
element	NULL
that	NULL
contains	NULL
PU.1	NULL
and	NULL
a	NULL
recently	NULL
cloned	NULL
interacting	NULL
protein	NULL
termed	NULL
Pip	NULL
.	NULL

PU.1	NULL
and	NULL
Pip	NULL
bind	NULL
to	NULL
the	NULL
CD20	NULL
promoter	NULL
in	NULL
a	NULL
cooperative	NULL
manner	NULL
and	NULL
the	NULL
PU.1/Pip	NULL
element	NULL
appears	NULL
critical	NULL
for	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
other	NULL
element	NULL
is	NULL
a	NULL
wE3	NULL
site	NULL
located	NULL
proximally	NULL
in	NULL
the	NULL
CD20	NULL
promoter	NULL
,	NULL
which	NULL
binds	NULL
members	NULL
of	NULL
the	NULL
bHLHZ	NULL
family	NULL
.	NULL

Although	NULL
these	NULL
factors	NULL
are	NULL
expressed	NULL
ubiquitously	NULL
,	NULL
in	NULL
vivo	NULL
footprinting	NULL
experiments	NULL
indicate	NULL
that	NULL
this	NULL
element	NULL
is	NULL
only	NULL
occupied	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
bHLHZ	NULL
protein	NULL
USF	NULL
strongly	NULL
transactivates	NULL
the	NULL
CD20	NULL
promoter	NULL
through	NULL
the	NULL
E3	NULL
site	NULL
.	NULL

PU.1	NULL
is	NULL
the	NULL
product	NULL
of	NULL
the	NULL
Spi-1	NULL
proto-oncogene	NULL
and	NULL
a	NULL
member	NULL
of	NULL
the	NULL
Ets	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL
``	NULL

''	NULL
The	NULL
PU.1	NULL
gene	NULL
is	NULL
expressed	NULL
specifically	NULL
in	NULL
hematopoietic	NULL
tissues	NULL
with	NULL
high	NULL
levels	NULL
in	NULL
the	NULL
monocytic	NULL
and	NULL
B-lymphoid	NULL
lin-eage	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
In	NULL
accordance	NULL
with	NULL
its	NULL
expression	NULL
pattern	NULL
,	NULL
gene	NULL
targeting	NULL
in	NULL
mouse	NULL
embryonic	NULL
stem	NULL
cells	NULL
showed	NULL
a	NULL
requirement	NULL
for	NULL
PU.1	NULL
for	NULL
multiple	NULL
hematopoietic	NULL
lineages	NULL
.	NULL
'	NULL

''	NULL
Among	NULL
the	NULL
various	NULL
Ets	NULL
family	NULL
members	NULL
,	NULL
PU.1	NULL
has	NULL
the	NULL
weakest	NULL
homology	NULL
to	NULL
the	NULL
consensus	NULL
Ets	NULL
domain	NULL
,	NULL
which	NULL
mediates	NULL
sequence-spe-cific	NULL
DNA	NULL
binding	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
is	NULL
the	NULL
observation	NULL
that	NULL
PU.1	NULL
binds	NULL
a	NULL
purine-rich	NULL
region	NULL
containing	NULL
the	NULL
minimal	NULL
sequence	NULL
AGAA	NULL
and	NULL
does	NULL
not	NULL
require	NULL
the	NULL
Ets	NULL
consensus	NULL
sequence	NULL
GGAA/T	NULL
.	NULL

**	NULL
As	NULL
with	NULL
other	NULL
Ets	NULL
proteins	NULL
the	NULL
sequence	NULL
surrounding	NULL
this	NULL
minimal	NULL
AGAA	NULL
sequence	NULL
is	NULL
important	NULL
for	NULL
the	NULL
affinity	NULL
of	NULL
PU.1	NULL
for	NULL
a	NULL
particular	NULL
binding	NULL
site	NULL
.	NULL

Numerous	NULL
presumptive	NULL
PU.1	NULL
target	NULL
genes	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

REGULATION	NULL
OF	NULL
CD20	NULL
PROMOTER	NULL
B	NULL
lymphoid	NULL
and	NULL
the	NULL
monocytic	NULL
lineages	NULL
.	NULL
``	NULL

Furthermore	NULL
,	NULL
PU.1	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
interact	NULL
with	NULL
multiple	NULL
proteins	NULL
to	NULL
exert	NULL
its	NULL
function	NULL
as	NULL
a	NULL
transcriptional	NULL
regulator	NULL
.	NULL
``	NULL

A	NULL
particularly	NULL
interesting	NULL
protein-protein	NULL
interaction	NULL
for	NULL
understanding	NULL
the	NULL
role	NULL
of	NULL
PU.1	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
B-cell-specific	NULL
genes	NULL
is	NULL
its	NULL
interaction	NULL
with	NULL
Pip	NULL
,	NULL
initially	NULL
called	NULL
NF-EM5	NULL
,	NULL
on	NULL
a	NULL
conserved	NULL
tissue-specific	NULL
composite	NULL
element	NULL
present	NULL
in	NULL
the	NULL
Ig	NULL
light	NULL
chain	NULL
enhancers	NULL
x	NULL
3	NULL
'	NULL
,	NULL
A2-4	NULL
,	NULL
and	NULL
\3-1	NULL
.	NULL

``	NULL
Â°	NULL
``	NULL
Participation	NULL
of	NULL
Pip	NULL
in	NULL
this	NULL
complex	NULL
depends	NULL
on	NULL
DNA-bound	NULL
PU.1	NULL
and	NULL
phosphorylation	NULL
of	NULL
PU.1	NULL
at	NULL
serine	NULL
residue	NULL
148	NULL
.	NULL
``	NULL

Competition	NULL
experiments	NULL
showed	NULL
that	NULL
PU.1	NULL
and	NULL
Pip	NULL
bound	NULL
their	NULL
composite	NULL
element	NULL
in	NULL
a	NULL
cooperative	NULL
fashion	NULL
.	NULL

Pip	NULL
is	NULL
expressed	NULL
in	NULL
both	NULL
B	NULL
cells	NULL
and	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
based	NULL
on	NULL
sequence	NULL
homology	NULL
it	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
interferon	NULL
regulatory	NULL
factor	NULL
(	NULL
IRF	NULL
)	NULL
family	NULL
.	NULL

Among	NULL
the	NULL
IRF	NULL
family	NULL
members	NULL
Pip	NULL
is	NULL
most	NULL
related	NULL
to	NULL
interferon	NULL
consensus	NULL
sequence-binding	NULL
protein	NULL
(	NULL
ICSBP	NULL
)	NULL
because	NULL
they	NULL
share	NULL
83	NULL
%	NULL
amino	NULL
acid	NULL
identity	NULL
within	NULL
their	NULL
respective	NULL
DNA	NULL
binding	NULL
domains	NULL
.	NULL
``	NULL

ICSBP	NULL
is	NULL
a	NULL
lymphoid-myeloid	NULL
restrictive	NULL
repressor	NULL
of	NULL
interferon-induced	NULL
transcription	NULL
and	NULL
,	NULL
like	NULL
Pip	NULL
,	NULL
is	NULL
recruited	NULL
to	NULL
the	NULL
Ig	NULL
light	NULL
chain	NULL
composite	NULL
element	NULL
by	NULL
PU.1	NULL
.	NULL

**	NULL
In	NULL
contrast	NULL
to	NULL
Pip	NULL
,	NULL
ICSBP	NULL
did	NULL
not	NULL
enhance	NULL
PU.1-induced	NULL
transcription	NULL
of	NULL
a	NULL
reporter	NULL
plasmid	NULL
containing	NULL
a	NULL
minimal	NULL
promoter	NULL
linked	NULL
to	NULL
a	NULL
tetramer	NULL
of	NULL
the	NULL
AB	NULL
site	NULL
.	NULL
``	NULL

''	NULL
Using	NULL
a	NULL
Pip-specific	NULL
antiserum	NULL
,	NULL
Pip	NULL
was	NULL
found	NULL
to	NULL
be	NULL
the	NULL
major	NULL
component	NULL
associating	NULL
with	NULL
PU.1	NULL
on	NULL
the	NULL
AB	NULL
site	NULL
in	NULL
the	NULL
murine	NULL
myeloma	NULL
cell	NULL
line	NULL
J55L	NULL
.	NULL

``	NULL
Â°	NULL
In	NULL
preliminary	NULL
experiments	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
PU.1/ICSBP	NULL
also	NULL
binds	NULL
the	NULL
CD20	NULL
PU.1/Pip	NULL
site	NULL
,	NULL
and	NULL
that	NULL
together	NULL
they	NULL
weakly	NULL
transactivate	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
ICSBP	NULL
to	NULL
PU.1	NULL
and	NULL
Pip	NULL
more	NULL
potently	NULL
transactivated	NULL
the	NULL
CD20	NULL
promoter	NULL
construct	NULL
than	NULL
did	NULL
PU.1	NULL
and	NULL
Pip	NULL
alone	NULL
(	NULL
A.	NULL
Riva	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
whereas	NULL
Pip	NULL
and	NULL
PU.1	NULL
appear	NULL
to	NULL
be	NULL
the	NULL
major	NULL
components	NULL
of	NULL
complex	NULL
24	NULL
,	NULL
ICSBP	NULL
may	NULL
also	NULL
in	NULL
conjunction	NULL
with	NULL
PU.1	NULL
bind	NULL
to	NULL
the	NULL
CD20	NULL
promoter	NULL
and	NULL
contribute	NULL
to	NULL
its	NULL
regulation	NULL
.	NULL

The	NULL
PU.1/Pip	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
CD20	NULL
promoter	NULL
is	NULL
homologous	NULL
to	NULL
the	NULL
element	NULL
described	NULL
in	NULL
the	NULL
Ig	NULL
light	NULL
chain	NULL
en-hancers	NULL
,	NULL
but	NULL
it	NULL
lacks	NULL
an	NULL
Ets	NULL
consensus	NULL
sequence	NULL
.	NULL

Thus	NULL
,	NULL
distinguishing	NULL
the	NULL
CD20	NULL
element	NULL
is	NULL
the	NULL
fact	NULL
that	NULL
PU.1	NULL
binds	NULL
it	NULL
very	NULL
poorly	NULL
unless	NULL
Pip	NULL
or	NULL
ICSBP	NULL
is	NULL
present	NULL
.	NULL

This	NULL
may	NULL
account	NULL
for	NULL
why	NULL
the	NULL
addition	NULL
of	NULL
ICSBP	NULL
to	NULL
PU.1	NULL
transactivated	NULL
the	NULL
CD20	NULL
promoter	NULL
construct	NULL
,	NULL
but	NULL
failed	NULL
to	NULL
alter	NULL
PU.1-induced	NULL
activation	NULL
of	NULL
the	NULL
AB	NULL
tetramer	NULL
.	NULL
``	NULL

''	NULL
Together	NULL
PU.1	NULL
and	NULL
Pip	NULL
bound	NULL
the	NULL
CD20	NULL
element	NULL
with	NULL
high	NULL
affinity	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
earlier	NULL
observation	NULL
of	NULL
cooperative	NULL
binding	NULL
of	NULL
the	NULL
two	NULL
proteins	NULL
.	NULL

Because	NULL
B	NULL
lymphocytes	NULL
express	NULL
both	NULL
PU.1	NULL
and	NULL
Pip	NULL
,	NULL
PU.1	NULL
will	NULL
bind	NULL
the	NULL
CD20	NULL
promoter	NULL
element	NULL
with	NULL
high	NULL
affinity	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

Evidence	NULL
for	NULL
the	NULL
critical	NULL
importance	NULL
of	NULL
the	NULL
PU.1/Pip	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
B-cell-specific	NULL
expression	NULL
of	NULL
the	NULL
CD20	NULL
gene	NULL
was	NULL
provided	NULL
by	NULL
several	NULL
different	NULL
experiments	NULL
.	NULL

First	NULL
,	NULL
this	NULL
element	NULL
was	NULL
occupied	NULL
in	NULL
vivo	NULL
only	NULL
in	NULL
CD20-expressing	NULL
B	NULL
cells	NULL
.	NULL

Second	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
element	NULL
in	NULL
a	NULL
reporter	NULL
plasmid	NULL
nearly	NULL
completely	NULL
abolished	NULL
promoter	NULL
function	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

Third	NULL
,	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
detected	NULL
with	NULL
the	NULL
CD20	NULL
probe	NULL
seems	NULL
to	NULL
be	NULL
developmentally	NULL
regulated	NULL
in	NULL
a	NULL
manner	NULL
similar	NULL
to	NULL
CD20	NULL
.	NULL

Mature	NULL
CD20-positive	NULL
B-cell	NULL
lines	NULL
contained	NULL
a	NULL
PU.1/Pip	NULL
complex	NULL
whereas	NULL
the	NULL
immature	NULL
CD20-negative	NULL
B-cell	NULL
lines	NULL
and	NULL
a	NULL
CD20-negative	NULL
myeloma	NULL
cell	NULL
line	NULL
lacked	NULL
it	NULL
.	NULL

3993	NULL
The	NULL
PU.1/Pip	NULL
complex	NULL
negative	NULL
cell	NULL
lines	NULL
PB697	NULL
and	NULL
RPMI	NULL
8226	NULL
contained	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
PU.1	NULL
and	NULL
adding	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
to	NULL
nuclear	NULL
extracts	NULL
reconstituted	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
.	NULL

The	NULL
undetectable	NULL
level	NULL
of	NULL
PU.1	NULL
in	NULL
PB697	NULL
cells	NULL
was	NULL
surprising	NULL
because	NULL
PU.1	NULL
has	NULL
been	NULL
found	NULL
in	NULL
other	NULL
pre-B	NULL
and	NULL
pro-B	NULL
cell	NULL
lines	NULL
,	NULL
whereas	NULL
the	NULL
undetectable	NULL
level	NULL
in	NULL
the	NULL
plasmacytoma	NULL
cell	NULL
line	NULL
,	NULL
RPMI	NULL
$	NULL
226	NULL
,	NULL
is	NULL
consistent	NULL
with	NULL
a	NULL
recent	NULL
report	NULL
that	NULL
showed	NULL
low	NULL
or	NULL
absent	NULL
PU.1	NULL
levels	NULL
in	NULL
a	NULL
panel	NULL
of	NULL
human	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL
``	NULL

''	NULL
This	NULL
observation	NULL
suggests	NULL
that	NULL
PU.1	NULL
is	NULL
downregulated	NULL
during	NULL
the	NULL
terminal	NULL
stages	NULL
of	NULL
B-cell	NULL
differentiation	NULL
,	NULL
thus	NULL
,	NULL
perhaps	NULL
accounting	NULL
for	NULL
the	NULL
lack	NULL
of	NULL
CD20	NULL
gene	NULL
expression	NULL
in	NULL
plasma	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
these	NULL
results	NULL
differ	NULL
from	NULL
findings	NULL
in	NULL
the	NULL
murine	NULL
system	NULL
in	NULL
which	NULL
PU.1	NULL
is	NULL
present	NULL
and	NULL
active	NULL
in	NULL
most	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL
``	NULL

''	NULL
In	NULL
contrast	NULL
to	NULL
the	NULL
pre-B-cell	NULL
line	NULL
PB697	NULL
cells	NULL
,	NULL
the	NULL
pre-B	NULL
cell	NULL
line	NULL
NALM-6	NULL
contained	NULL
high	NULL
PU.1	NULL
levels	NULL
both	NULL
by	NULL
EMSA	NULL
and	NULL
immunoblotting	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
lysate	NULL
from	NULL
this	NULL
cell	NULL
line	NULL
lacked	NULL
several	NULL
faint	NULL
bands	NULL
of	NULL
slower	NULL
mobility	NULL
that	NULL
were	NULL
detected	NULL
with	NULL
the	NULL
lysates	NULL
from	NULL
the	NULL
mature	NULL
B-cell	NULL
lines	NULL
and	NULL
with	NULL
the	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
.	NULL

These	NULL
faint	NULL
bands	NULL
may	NULL
represent	NULL
different	NULL
phosphorylated	NULL
isoforms	NULL
of	NULL
PU.1	NULL
.	NULL

Because	NULL
phosphorylation	NULL
of	NULL
serine	NULL
148	NULL
in	NULL
PU.1	NULL
is	NULL
necessary	NULL
for	NULL
the	NULL
PU.1/Pip	NULL
interaction	NULL
,	NULL
``	NULL
``	NULL
the	NULL
lack	NULL
of	NULL
such	NULL
a	NULL
phosphorylation	NULL
may	NULL
account	NULL
for	NULL
the	NULL
lack	NULL
of	NULL
a	NULL
PU.1/Pip	NULL
complex	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

Also	NULL
consistent	NULL
with	NULL
this	NULL
possibility	NULL
is	NULL
the	NULL
observation	NULL
that	NULL
in	NULL
vitro	NULL
translated	NULL
PU.1	NULL
,	NULL
which	NULL
is	NULL
phosphorylated	NULL
at	NULL
serine	NULL
148	NULL
,	NULL
``	NULL
``	NULL
rescues	NULL
the	NULL
PU.1/Pip	NULL
complex	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

Further	NULL
experiments	NULL
are	NULL
in	NULL
progress	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
lack	NULL
of	NULL
serine	NULL
148	NULL
phosphorylation	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
failure	NULL
to	NULL
detect	NULL
a	NULL
PU.1/Pip	NULL
interaction	NULL
in	NULL
NALM-6	NULL
cells	NULL
.	NULL

Although	NULL
these	NULL
data	NULL
define	NULL
a	NULL
critical	NULL
function	NULL
of	NULL
the	NULL
PU.1/	NULL
Pip	NULL
interaction	NULL
for	NULL
CD20	NULL
gene	NULL
expression	NULL
,	NULL
we	NULL
found	NULL
only	NULL
a	NULL
weak	NULL
(	NULL
2-	NULL
to	NULL
3-fold	NULL
)	NULL
transactivation	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
by	NULL
PU.1	NULL
and	NULL
Pip	NULL
in	NULL
NIH	NULL
3T3	NULL
cells	NULL
.	NULL

This	NULL
may	NULL
be	NULL
secondary	NULL
to	NULL
the	NULL
lack	NULL
of	NULL
another	NULL
factor	NULL
in	NULL
the	NULL
NIH	NULL
3T3	NULL
cells	NULL
.	NULL

Several	NULL
experiments	NULL
have	NULL
indicated	NULL
that	NULL
the	NULL
Ets	NULL
proteins	NULL
in	NULL
general	NULL
are	NULL
poor	NULL
transcriptional	NULL
activators	NULL
and	NULL
often	NULL
function	NULL
as	NULL
part	NULL
of	NULL
multiprotein	NULL
complexes	NULL
.	NULL
``	NULL

Given	NULL
the	NULL
apparent	NULL
weak	NULL
transactivation	NULL
potential	NULL
of	NULL
PU.1	NULL
it	NULL
has	NULL
been	NULL
hypothesized	NULL
that	NULL
the	NULL
primary	NULL
function	NULL
of	NULL
PU.1	NULL
is	NULL
to	NULL
recruit	NULL
other	NULL
transcription	NULL
factors	NULL
to	NULL
a	NULL
gene	NULL
regulatory	NULL
element	NULL
.	NULL

This	NULL
function	NULL
could	NULL
be	NULL
carried	NULL
out	NULL
either	NULL
through	NULL
direct	NULL
protein-protein	NULL
interactions	NULL
or	NULL
through	NULL
indirect	NULL
mechanisms	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
cooperative	NULL
activation	NULL
of	NULL
a	NULL
reporter	NULL
construct	NULL
containing	NULL
the	NULL
A	NULL
and	NULL
LB	NULL
site	NULL
of	NULL
the	NULL
IgH	NULL
intronic	NULL
enhancer	NULL
by	NULL
PU.1	NULL
and	NULL
Ets-1	NULL
has	NULL
been	NULL
described	NULL
that	NULL
required	NULL
only	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
PU.1.538	NULL
Similarly	NULL
,	NULL
it	NULL
is	NULL
conceivable	NULL
that	NULL
formation	NULL
of	NULL
the	NULL
PU.1/	NULL
Pip	NULL
complex	NULL
recruits	NULL
other	NULL
transcription	NULL
factors	NULL
to	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

Our	NULL
finding	NULL
that	NULL
a	NULL
E3	NULL
site	NULL
in	NULL
the	NULL
CD20	NULL
promoter	NULL
is	NULL
occupied	NULL
only	NULL
in	NULL
B	NULL
cells	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
PU.1\Pip	NULL
complex	NULL
regulates	NULL
the	NULL
accessibility	NULL
of	NULL
the	NULL
ubiquitous	NULL
E3	NULL
binding	NULL
proteins	NULL
to	NULL
this	NULL
site	NULL
in	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

Although	NULL
expression	NULL
of	NULL
the	NULL
E3	NULL
binding	NULL
proteins	NULL
is	NULL
not	NULL
restricted	NULL
to	NULL
B	NULL
cells	NULL
,	NULL
there	NULL
is	NULL
evidence	NULL
that	NULL
these	NULL
transcription	NULL
factors	NULL
can	NULL
participate	NULL
in	NULL
B-cell-specific	NULL
gene	NULL
transcription	NULL
.	NULL

The	NULL
wE3	NULL
site	NULL
was	NULL
initially	NULL
defined	NULL
by	NULL
in	NULL
vivo	NULL
genomic	NULL
footprinting	NULL
as	NULL
an	NULL
element	NULL
of	NULL
the	NULL
IgH	NULL
intronic	NULL
enhancer	NULL
that	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3994	NULL
interacted	NULL
with	NULL
binding	NULL
proteins	NULL
only	NULL
in	NULL
B	NULL
cells	NULL
``	NULL
``	NULL
compara-	NULL
ble	NULL
with	NULL
the	NULL
situation	NULL
in	NULL
the	NULL
CD20	NULL
promoter	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
the	NULL
IgH	NULL
intronic	NULL
enhancer	NULL
has	NULL
shown	NULL
that	NULL
the	NULL
E3	NULL
element	NULL
is	NULL
responsible	NULL
for	NULL
about	NULL
30	NULL
%	NULL
of	NULL
the	NULL
enhancer	NULL
activity	NULL
in	NULL
B	NULL
cells	NULL
.	NULL
``	NULL

A	NULL
number	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
E3	NULL
site	NULL
have	NULL
been	NULL
isolated	NULL
,	NULL
among	NULL
them	NULL
TFE3	NULL
,	NULL
***	NULL
USF	NULL
,	NULL
``	NULL
and	NULL
TFEB	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
Ig	NULL
genes	NULL
,	NULL
these	NULL
factors	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
a	NULL
number	NULL
of	NULL
genes	NULL
,	NULL
*	NULL
``	NULL
``	NULL
``	NULL
but	NULL
CD20	NULL
is	NULL
the	NULL
only	NULL
other	NULL
B-cell-specific	NULL
gene	NULL
.	NULL

Our	NULL
in	NULL
vivo	NULL
footprinting	NULL
data	NULL
,	NULL
gel	NULL
shift	NULL
data	NULL
,	NULL
along	NULL
with	NULL
the	NULL
strong	NULL
transactivation	NULL
of	NULL
the	NULL
CD20	NULL
promoter	NULL
by	NULL
USF1	NULL
support	NULL
the	NULL
notion	NULL
that	NULL
the	NULL
E3	NULL
element	NULL
and	NULL
USF1	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
regulating	NULL
the	NULL
B-cell-specific	NULL
expression	NULL
of	NULL
the	NULL
CD20	NULL
gene	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
novel	NULL
function	NULL
of	NULL
tethering	NULL
promoter	NULL
and	NULL
enhancer	NULL
elements	NULL
that	NULL
both	NULL
have	NULL
E3	NULL
sites	NULL
has	NULL
been	NULL
described	NULL
for	NULL
the	NULL
bHLHZ	NULL
protein	NULL
,	NULL
TFE3	NULL
.	NULL
``	NULL

We	NULL
have	NULL
made	NULL
CD20	NULL
promoter-reporter	NULL
constructs	NULL
that	NULL
contain	NULL
a	NULL
tetramer	NULL
of	NULL
E3	NULL
sites	NULL
in	NULL
an	NULL
enhancer	NULL
position	NULL
.	NULL

In	NULL
cotransfection	NULL
experiments	NULL
with	NULL
TFE3	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
function	NULL
of	NULL
this	NULL
artificial	NULL
enhancer	NULL
depended	NULL
on	NULL
an	NULL
intact	NULL
E3	NULL
site	NULL
in	NULL
the	NULL
CD20	NULL
promoter	NULL
,	NULL
supporting	NULL
the	NULL
model	NULL
that	NULL
TFE3	NULL
can	NULL
mediate	NULL
interactions	NULL
between	NULL
promoter	NULL
and	NULL
enhancer	NULL
elements	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
might	NULL
also	NULL
indicate	NULL
that	NULL
the	NULL
function	NULL
of	NULL
the	NULL
E3	NULL
site	NULL
in	NULL
the	NULL
CD20	NULL
promoter	NULL
is	NULL
to	NULL
facilitate	NULL
an	NULL
interaction	NULL
with	NULL
a	NULL
CD20	NULL
enhancer	NULL
.	NULL

Finally	NULL
,	NULL
it	NULL
is	NULL
interesting	NULL
to	NULL
observe	NULL
that	NULL
three	NULL
important	NULL
B-cell-specific	NULL
genes	NULL
that	NULL
are	NULL
first	NULL
transcriptionally	NULL
activated	NULL
during	NULL
the	NULL
pre-B-cell	NULL
stage	NULL
of	NULL
B-cell	NULL
development	NULL
,	NULL
the	NULL
two	NULL
light	NULL
chain	NULL
genes	NULL
and	NULL
the	NULL
CD20	NULL
gene	NULL
,	NULL
all	NULL
have	NULL
a	NULL
critical	NULL
PU.1/Pip	NULL
site	NULL
in	NULL
their	NULL
gene	NULL
regulatory	NULL
elements	NULL
.	NULL

This	NULL
observation	NULL
could	NULL
indicate	NULL
an	NULL
important	NULL
role	NULL
for	NULL
this	NULL
complex	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
genes	NULL
at	NULL
the	NULL
pre-B-cell	NULL
stage	NULL
of	NULL
B-cell	NULL
development	NULL
.	NULL

ACKNOWLEDGMENT	NULL
The	NULL
authors	NULL
thank	NULL
Dr	NULL
Anthony	NULL
Fauci	NULL
for	NULL
his	NULL
support	NULL
and	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
and	NULL
Ms	NULL
Mary	NULL
Rust	NULL
for	NULL
her	NULL
excellent	NULL
editorial	NULL
assistance	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Blackwell	NULL
TK	NULL
,	NULL
Alt	NULL
FW	NULL
:	NULL
Mechanism	NULL
and	NULL
developmental	NULL
program	NULL
of	NULL
immunoglobulin	NULL
gene	NULL
rearrangement	NULL
in	NULL
mammals	NULL
.	NULL

Annu	NULL
Rev	NULL
Genet	NULL
23:605	NULL
,	NULL
1989	NULL
2	NULL
.	NULL

Calame	NULL
K	NULL
,	NULL
Ghosh	NULL
S	NULL
:	NULL
Regulation	NULL
of	NULL
immunoglobulin	NULL
transcrip-tion	NULL
,	NULL
in	NULL
Honjo	NULL
T	NULL
,	NULL
Alt	NULL
FW	NULL
,	NULL
Rabbitts	NULL
TH	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Immunoglobulin	NULL
Genes	NULL
.	NULL

London	NULL
,	NULL
UK	NULL
,	NULL
Academic	NULL
Press	NULL
,	NULL
1989	NULL
,	NULL
p	NULL
397	NULL
3	NULL
.	NULL

Kehrl	NULL
JH	NULL
,	NULL
Riva	NULL
A	NULL
,	NULL
Wilson	NULL
GL	NULL
,	NULL
Thevenin	NULL
C	NULL
:	NULL
Molecular	NULL
mechanisms	NULL
regulating	NULL
CD19	NULL
,	NULL
CD20	NULL
and	NULL
CD22	NULL
gene	NULL
expression	NULL
.	NULL

Immunol	NULL
Today	NULL
15:432	NULL
,	NULL
1994	NULL
4	NULL
.	NULL

Hagman	NULL
J	NULL
,	NULL
Grosschedl	NULL
R	NULL
:	NULL
Regulation	NULL
of	NULL
gene	NULL
expression	NULL
at	NULL
early	NULL
stages	NULL
of	NULL
B	NULL
cell	NULL
differentiation	NULL
.	NULL

Curr	NULL
Opin	NULL
Immunol	NULL
6:222	NULL
,	NULL
1994	NULL
5	NULL
.	NULL

Singh	NULL
H	NULL
:	NULL
Genetic	NULL
analysis	NULL
of	NULL
transcription	NULL
factors	NULL
implicated	NULL
in	NULL
B	NULL
lymphocyte	NULL
development	NULL
.	NULL

Immunol	NULL
Res	NULL
13:280	NULL
,	NULL
1994	NULL
6	NULL
.	NULL

Ernst	NULL
P	NULL
,	NULL
Smale	NULL
ST	NULL
:	NULL
Combinatorial	NULL
regulation	NULL
of	NULL
transcription	NULL
II	NULL
:	NULL
The	NULL
immunoglobulin	NULL
&	NULL
heavy	NULL
chain	NULL
enhancer	NULL
.	NULL

Immunity	NULL
2:427	NULL
,	NULL
1995	NULL
7	NULL
.	NULL

Urbanek	NULL
P	NULL
,	NULL
Wang	NULL
ZQ	NULL
,	NULL
Fetka	NULL
I	NULL
,	NULL
Wagner	NULL
EF	NULL
,	NULL
Busslinger	NULL
M	NULL
:	NULL
Complete	NULL
block	NULL
of	NULL
early	NULL
B	NULL
cell	NULL
differentiation	NULL
and	NULL
altered	NULL
patterning	NULL
HIMMELMANN	NULL
ET	NULL
AL	NULL
of	NULL
the	NULL
posterior	NULL
midbrain	NULL
in	NULL
mice	NULL
lacking	NULL
Pax5/BSAP	NULL
.	NULL

Cell	NULL
79:901	NULL
,	NULL
1994	NULL
8	NULL
.	NULL

Lin	NULL
H	NULL
,	NULL
Grosschedl	NULL
R	NULL
:	NULL
Failure	NULL
of	NULL
B-cell	NULL
differentiation	NULL
in	NULL
mice	NULL
lacking	NULL
the	NULL
transcription	NULL
factor	NULL
EBF	NULL
.	NULL

Nature	NULL
376:263	NULL
,	NULL
1995	NULL
9	NULL
.	NULL

Zhuang	NULL
Y	NULL
,	NULL
Soriano	NULL
P	NULL
,	NULL
Weintraub	NULL
H	NULL
:	NULL
The	NULL
helix-loop-helix	NULL
gene	NULL
E2A	NULL
is	NULL
required	NULL
for	NULL
B	NULL
cell	NULL
formation	NULL
.	NULL

Cell	NULL
79:875	NULL
,	NULL
1994	NULL
10	NULL
.	NULL

Scott	NULL
EW	NULL
,	NULL
Simon	NULL
MC	NULL
,	NULL
Anastasi	NULL
J	NULL
,	NULL
Singh	NULL
H	NULL
:	NULL
Requirement	NULL
of	NULL
transcription	NULL
factor	NULL
PU.1	NULL
in	NULL
the	NULL
development	NULL
of	NULL
multiple	NULL
hematopoietic	NULL
lineages	NULL
.	NULL

Science	NULL
265:1573	NULL
,	NULL
1994	NULL
11	NULL
.	NULL

Georgopoulos	NULL
K	NULL
,	NULL
Bigby	NULL
M	NULL
,	NULL
Wang	NULL
J-H	NULL
,	NULL
Molnar	NULL
A	NULL
,	NULL
Wu	NULL
P	NULL
,	NULL
Winandy	NULL
S	NULL
,	NULL
Sharpe	NULL
A	NULL
:	NULL
The	NULL
Ikaros	NULL
gene	NULL
is	NULL
required	NULL
for	NULL
the	NULL
development	NULL
of	NULL
all	NULL
lymphoid	NULL
lineages	NULL
.	NULL

Cell	NULL
79:143	NULL
,	NULL
1994	NULL
12	NULL
.	NULL

Nadler	NULL
LM	NULL
,	NULL
Korsmeyer	NULL
SJ	NULL
,	NULL
Anderson	NULL
KC	NULL
,	NULL
Boyd	NULL
AW	NULL
,	NULL
Slaugh-enhoupt	NULL
B	NULL
,	NULL
Park	NULL
E	NULL
,	NULL
Jansen	NULL
J	NULL
,	NULL
Coral	NULL
F	NULL
,	NULL
Mayer	NULL
RJ	NULL
,	NULL
Sallan	NULL
SE	NULL
,	NULL
Ritz	NULL
J	NULL
,	NULL
Schlossman	NULL
S	NULL
:	NULL
B	NULL
cell	NULL
origin	NULL
of	NULL
non-T	NULL
cell	NULL
acute	NULL
lymphoblastic	NULL
leuke-mia	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
74:332	NULL
,	NULL
1984	NULL
13	NULL
.	NULL

Tedder	NULL
TF	NULL
,	NULL
Engel	NULL
P	NULL
:	NULL
CD20	NULL
:	NULL
A	NULL
regulator	NULL
of	NULL
cell-cycle	NULL
progression	NULL
of	NULL
B	NULL
lymphocytes	NULL
.	NULL

Immunol	NULL
Today	NULL
15:450	NULL
,	NULL
1994	NULL
14	NULL
.	NULL

Rickmann	NULL
P	NULL
,	NULL
Thevenin	NULL
C	NULL
,	NULL
Wilson	NULL
GL	NULL
,	NULL
Hong	NULL
JX	NULL
,	NULL
Kebrl	NULL
JH	NULL
:	NULL
Analysis	NULL
of	NULL
Cis-acting	NULL
elements	NULL
present	NULL
in	NULL
the	NULL
CD20/B1	NULL
antigen	NULL
promoter	NULL
.	NULL

J	NULL
Immunol	NULL
147:3994	NULL
,	NULL
1991	NULL
15	NULL
.	NULL

Tedder	NULL
TF	NULL
,	NULL
Klejman	NULL
G	NULL
,	NULL
Schlossman	NULL
SF	NULL
,	NULL
Saito	NULL
H	NULL
:	NULL
Structure	NULL
of	NULL
the	NULL
gene	NULL
encoding	NULL
the	NULL
human	NULL
B	NULL
lymphocyte	NULL
differentiation	NULL
antigen	NULL
CD20	NULL
(	NULL
B1	NULL
)	NULL
.	NULL

J	NULL
Immunol	NULL
142:2560	NULL
,	NULL
1989	NULL
16	NULL
.	NULL

Thevenin	NULL
C	NULL
,	NULL
Lucas	NULL
BP	NULL
,	NULL
Kozlow	NULL
EJ	NULL
,	NULL
Kebrl	NULL
JH	NULL
:	NULL
Cell	NULL
type-	NULL
and	NULL
stage-specific	NULL
expression	NULL
of	NULL
the	NULL
CD2/B1	NULL
antigen	NULL
correlates	NULL
with	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
diverged	NULL
octamer	NULL
DNA	NULL
motif	NULL
present	NULL
in	NULL
its	NULL
promoter	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
268:5949	NULL
,	NULL
1993	NULL
17	NULL
.	NULL

Corcoran	NULL
LM	NULL
,	NULL
Karvelas	NULL
M	NULL
,	NULL
Nossal	NULL
GJV	NULL
,	NULL
Ye	NULL
ZS	NULL
,	NULL
Jacks	NULL
T	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Oct-2	NULL
,	NULL
although	NULL
not	NULL
required	NULL
for	NULL
early	NULL
B-cell	NULL
development	NULL
,	NULL
is	NULL
critical	NULL
for	NULL
later	NULL
B-cell	NULL
maturation	NULL
and	NULL
for	NULL
postnatal	NULL
survival	NULL
.	NULL

Genes	NULL
Dev	NULL
7:570	NULL
,	NULL
1993	NULL
18	NULL
.	NULL

Mueller	NULL
PR	NULL
,	NULL
Wold	NULL
B	NULL
:	NULL
Ligation	NULL
mediated	NULL
PCR	NULL
for	NULL
genomic	NULL
sequencing	NULL
and	NULL
footprinting	NULL
,	NULL
in	NULL
Ausubal	NULL
F	NULL
(	NULL
ed	NULL
)	NULL
:	NULL
Current	NULL
Protocols	NULL
in	NULL
Molecular	NULL
Biology	NULL
.	NULL

New	NULL
York	NULL
,	NULL
NY	NULL
,	NULL
J	NULL
Wiley	NULL
and	NULL
Sons	NULL
,	NULL
1992	NULL
,	NULL
p	NULL
15.5.1	NULL
19	NULL
.	NULL

Dignam	NULL
JE	NULL
,	NULL
Martin	NULL
PI	NULL
,	NULL
Shastry	NULL
BS	NULL
,	NULL
Roeder	NULL
RG	NULL
:	NULL
Eukaryotic	NULL
gene	NULL
transcription	NULL
with	NULL
purified	NULL
components	NULL
.	NULL

Method	NULL
Enzymol	NULL
101:582	NULL
,	NULL
1983	NULL
20	NULL
.	NULL

Kadesch	NULL
T	NULL
:	NULL
Helix-loop-helix	NULL
proteins	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
immunoglobulin	NULL
gene	NULL
transcription	NULL
.	NULL

Immunol	NULL
Today	NULL
13:31	NULL
,	NULL
1992	NULL
21	NULL
.	NULL

Shin	NULL
MK	NULL
,	NULL
Koshland	NULL
ME	NULL
:	NULL
Ets-related	NULL
protein	NULL
PU.1	NULL
regulates	NULL
expression	NULL
of	NULL
the	NULL
immunoglobulin	NULL
J-chain	NULL
gene	NULL
through	NULL
a	NULL
novel	NULL
Ets-bindig	NULL
element	NULL
.	NULL

Genes	NULL
Dev	NULL
7:2006	NULL
,	NULL
1993	NULL
22	NULL
.	NULL

Pahl	NULL
HL	NULL
,	NULL
Scheibe	NULL
R	NULL
,	NULL
Zhang	NULL
D	NULL
,	NULL
Chen	NULL
HM	NULL
,	NULL
Galson	NULL
DL	NULL
,	NULL
Maki	NULL
RA	NULL
,	NULL
Tenen	NULL
DG	NULL
:	NULL
The	NULL
proto-oncogene	NULL
PU.1	NULL
regulates	NULL
expression	NULL
of	NULL
the	NULL
myeloid-specific	NULL
CD11b	NULL
promoter	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
268:5014	NULL
,	NULL
1993	NULL
23	NULL
.	NULL

Petterson	NULL
M	NULL
,	NULL
Schaffner	NULL
W	NULL
:	NULL
A	NULL
purine-rich	NULL
DNA	NULL
sequence	NULL
motif	NULL
present	NULL
in	NULL
SV	NULL
40	NULL
and	NULL
lymphotropic	NULL
papovavirus	NULL
binds	NULL
a	NULL
lymphoid-specific	NULL
factor	NULL
and	NULL
contributes	NULL
to	NULL
enhancer	NULL
activity	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Genes	NULL
Dev	NULL
1:962	NULL
,	NULL
1987	NULL
24	NULL
.	NULL

Eisenbeis	NULL
CF	NULL
,	NULL
Singh	NULL
H	NULL
,	NULL
Storb	NULL
U	NULL
:	NULL
Pip	NULL
,	NULL
a	NULL
novel	NULL
IRF	NULL
family	NULL
member	NULL
is	NULL
a	NULL
lymphoid-specific	NULL
,	NULL
PU.1-dependent	NULL
transcriptional	NULL
acti-vator	NULL
.	NULL

Genes	NULL
Dev	NULL
9:1377	NULL
,	NULL
1995	NULL
25	NULL
.	NULL

Klemsz	NULL
MJ	NULL
,	NULL
McKercher	NULL
SR	NULL
,	NULL
Celada	NULL
A	NULL
,	NULL
Van	NULL
Beveren	NULL
C	NULL
,	NULL
Maki	NULL
RA	NULL
:	NULL
The	NULL
macrophage	NULL
and	NULL
B	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
is	NULL
related	NULL
to	NULL
the	NULL
Ets	NULL
oncogene	NULL
.	NULL

Cell	NULL
61:113	NULL
,	NULL
1990	NULL
26	NULL
.	NULL

Moreau-Gachelin	NULL
F	NULL
,	NULL
Tavitian	NULL
A	NULL
,	NULL
Tambourin	NULL
P	NULL
:	NULL
Spi-1	NULL
is	NULL
a	NULL
putative	NULL
oncogene	NULL
in	NULL
virally	NULL
induced	NULL
murine	NULL
erythroleukemias	NULL
.	NULL

Nature	NULL
331:277	NULL
,	NULL
1988	NULL
27	NULL
.	NULL

Hromas	NULL
R	NULL
,	NULL
Orazi	NULL
A	NULL
,	NULL
Neiman	NULL
R	NULL
,	NULL
Maki	NULL
R	NULL
,	NULL
Van	NULL
Beveren	NULL
C	NULL
,	NULL
Moore	NULL
J	NULL
,	NULL
Klemsz	NULL
M	NULL
:	NULL
Hematopoietic	NULL
lineage-	NULL
and	NULL
stage-restricted	NULL
expression	NULL
of	NULL
the	NULL
ETS	NULL
oncogene	NULL
family	NULL
member	NULL
PU.I	NULL
.	NULL

Blood	NULL
82:2998	NULL
,	NULL
1993	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

REGULATION	NULL
OF	NULL
CD20	NULL
PROMOTER	NULL
28	NULL
.	NULL

Moreau-Gachelin	NULL
F	NULL
:	NULL
Spi-1/Pu.1	NULL
:	NULL
An	NULL
oncogene	NULL
of	NULL
the	NULL
Ets	NULL
family	NULL
.	NULL

Biochim	NULL
Biophys	NULL
Acta	NULL
1198:149	NULL
,	NULL
1994	NULL
29	NULL
.	NULL

Eisenbeis	NULL
CF	NULL
,	NULL
Singh	NULL
H	NULL
,	NULL
Storb	NULL
U	NULL
:	NULL
PU.1	NULL
is	NULL
a	NULL
component	NULL
of	NULL
a	NULL
multiprotein	NULL
complex	NULL
which	NULL
binds	NULL
an	NULL
essential	NULL
site	NULL
in	NULL
the	NULL
murine	NULL
immunoglobulin	NULL
2-4	NULL
enhancer	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
13:6452	NULL
,	NULL
1993	NULL
30	NULL
.	NULL

Hagemeier	NULL
C	NULL
,	NULL
Bannister	NULL
AJ	NULL
,	NULL
Cook	NULL
A	NULL
,	NULL
Kouzarides	NULL
T	NULL
:	NULL
The	NULL
activation	NULL
domain	NULL
of	NULL
transcription	NULL
factor	NULL
PU.1	NULL
binds	NULL
the	NULL
retinoblastoma	NULL
(	NULL
RB	NULL
)	NULL
protein	NULL
and	NULL
the	NULL
transcription	NULL
factor	NULL
TFIID	NULL
in	NULL
vitro	NULL
:	NULL
RB	NULL
shows	NULL
sequence	NULL
similarity	NULL
to	NULL
TFIID	NULL
and	NULL
TFIIB	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
90:1580	NULL
,	NULL
1993	NULL
31	NULL
.	NULL

Nagulapalli	NULL
S	NULL
,	NULL
Pongubala	NULL
JM	NULL
,	NULL
Atchison	NULL
ML	NULL
:	NULL
Multiple	NULL
proteins	NULL
physically	NULL
interact	NULL
with	NULL
PU.1	NULL
.	NULL

Transcriptional	NULL
synergy	NULL
with	NULL
NF-IL6	NULL
beta	NULL
(	NULL
C/EBP	NULL
delta	NULL
,	NULL
CRP3	NULL
)	NULL
.	NULL

J	NULL
Immunol	NULL
155:4330	NULL
,	NULL
1995	NULL
32	NULL
.	NULL

Pongubala	NULL
JR	NULL
,	NULL
Nagulapalli	NULL
S	NULL
,	NULL
Klemsz	NULL
MJ	NULL
,	NULL
McKercher	NULL
SR	NULL
,	NULL
Maki	NULL
RA	NULL
,	NULL
Atchinson	NULL
ML	NULL
:	NULL
PU.1	NULL
recruits	NULL
a	NULL
second	NULL
nuclear	NULL
factor	NULL
to	NULL
a	NULL
site	NULL
important	NULL
for	NULL
immunoglobulin	NULL
Â«	NULL
3	NULL
'	NULL
enhancer	NULL
activity	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
12:368	NULL
,	NULL
1992	NULL
33	NULL
.	NULL

Pongubala	NULL
JM	NULL
,	NULL
VanBeveren	NULL
C	NULL
,	NULL
Nagulapalli	NULL
S	NULL
,	NULL
Klemsz	NULL
MJ	NULL
,	NULL
McKercher	NULL
SR	NULL
,	NULL
Maki	NULL
RA	NULL
,	NULL
Atchison	NULL
ML	NULL
:	NULL
Effect	NULL
of	NULL
PU.1	NULL
phosphorylation	NULL
on	NULL
interaction	NULL
with	NULL
NF-EMS5	NULL
and	NULL
transcriptional	NULL
activation	NULL
.	NULL

Science	NULL
259:1622	NULL
,	NULL
1993	NULL
34	NULL
.	NULL

Driggers	NULL
P	NULL
,	NULL
Ennist	NULL
D	NULL
,	NULL
Gleason	NULL
S	NULL
,	NULL
Mak	NULL
WH	NULL
,	NULL
Marks	NULL
M	NULL
,	NULL
Levi	NULL
BZ	NULL
,	NULL
Flanagan	NULL
J	NULL
,	NULL
Appella	NULL
E	NULL
,	NULL
Ozato	NULL
K	NULL
:	NULL
An	NULL
interferon	NULL
y-regulated	NULL
protein	NULL
that	NULL
binds	NULL
the	NULL
interferon-inducible	NULL
enhancer	NULL
element	NULL
of	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I	NULL
genes	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
87:3743	NULL
,	NULL
1990	NULL
35	NULL
.	NULL

Nelson	NULL
N	NULL
,	NULL
Marks	NULL
M	NULL
,	NULL
Driggers	NULL
P	NULL
,	NULL
Ozato	NULL
K	NULL
:	NULL
Interferon	NULL
consensus	NULL
sequence-binding	NULL
protein	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
interferon	NULL
regulatory	NULL
factor	NULL
family	NULL
suppresses	NULL
interferon-in-induced	NULL
gene	NULL
transcription	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
16:694	NULL
,	NULL
1993	NULL
36	NULL
.	NULL

Brass	NULL
AL	NULL
,	NULL
Kebhrli	NULL
E	NULL
,	NULL
Eisenbeis	NULL
CF	NULL
,	NULL
Storb	NULL
U	NULL
,	NULL
Singh	NULL
H	NULL
:	NULL
Pip	NULL
,	NULL
a	NULL
lymphoid-restricted	NULL
IRF	NULL
,	NULL
contains	NULL
a	NULL
regulatory	NULL
domain	NULL
that	NULL
is	NULL
important	NULL
for	NULL
autoinhibition	NULL
and	NULL
ternary	NULL
complex	NULL
formation	NULL
with	NULL
the	NULL
Ets	NULL
factor	NULL
PU.1	NULL
.	NULL

Genes	NULL
Dev	NULL
10:2335	NULL
,	NULL
1996	NULL
37	NULL
.	NULL

Pettersson	NULL
M	NULL
,	NULL
Sundstrom	NULL
C	NULL
,	NULL
Nilsson	NULL
K	NULL
,	NULL
Larsson	NULL
LG	NULL
:	NULL
The	NULL
hematopoietic	NULL
transcription	NULL
factor	NULL
PU.1	NULL
is	NULL
downregulated	NULL
in	NULL
human	NULL
multiple	NULL
myeloma	NULL
cell	NULL
lines	NULL
.	NULL

Blood	NULL
86:2747	NULL
,	NULL
1995	NULL
38	NULL
.	NULL

Nelsen	NULL
B	NULL
,	NULL
Tian	NULL
G	NULL
,	NULL
Eman	NULL
B	NULL
,	NULL
Gregoire	NULL
J	NULL
,	NULL
Maki	NULL
R	NULL
,	NULL
Graves	NULL
B	NULL
,	NULL
Sen	NULL
R	NULL
:	NULL
Regulation	NULL
of	NULL
lymphoid-specific	NULL
immunoglobulin	NULL
mu	NULL
heavy	NULL
chain	NULL
gene	NULL
enhancer	NULL
by	NULL
ETS-domain	NULL
proteins	NULL
.	NULL

Science	NULL
261:82	NULL
,	NULL
1993	NULL
3995	NULL
39	NULL
.	NULL

Crepieux	NULL
P	NULL
,	NULL
Coll	NULL
J	NULL
,	NULL
Stehelin	NULL
D	NULL
:	NULL
The	NULL
Ets	NULL
family	NULL
of	NULL
proteins	NULL
:	NULL
Weak	NULL
modulators	NULL
of	NULL
gene	NULL
transcription	NULL
in	NULL
quest	NULL
for	NULL
transcriptional	NULL
partners	NULL
.	NULL

Crit	NULL
Rev	NULL
Oncol	NULL
5:615	NULL
,	NULL
1994	NULL
40	NULL
.	NULL

Church	NULL
GM	NULL
,	NULL
Ephrussi	NULL
A	NULL
,	NULL
Gilbert	NULL
W	NULL
,	NULL
Tonegawa	NULL
S	NULL
:	NULL
Cell-type-specific	NULL
contacts	NULL
to	NULL
immunoglobulin	NULL
enhancers	NULL
in	NULL
nuclei	NULL
.	NULL

Nature	NULL
313:798	NULL
,	NULL
1985	NULL
41	NULL
.	NULL

Ephrussi	NULL
A	NULL
,	NULL
Church	NULL
GM	NULL
,	NULL
Tonegawa	NULL
S	NULL
,	NULL
Gilbert	NULL
W	NULL
:	NULL
B	NULL
lincage-specific	NULL
interactions	NULL
of	NULL
an	NULL
immunoglobulin	NULL
enhancer	NULL
with	NULL
cellular	NULL
factors	NULL
in	NULL
vivo	NULL
.	NULL

Science	NULL
227:134	NULL
,	NULL
1985	NULL
42	NULL
.	NULL

Beckmann	NULL
H	NULL
,	NULL
Su	NULL
L-K	NULL
,	NULL
Kadesch	NULL
T	NULL
:	NULL
TFE3	NULL
:	NULL
A	NULL
helix-loop-helix	NULL
protein	NULL
that	NULL
activates	NULL
transcription	NULL
through	NULL
the	NULL
immunoglobulin	NULL
enhancer	NULL
4E3	NULL
motif	NULL
.	NULL

Genes	NULL
Dev	NULL
4:167	NULL
,	NULL
1990	NULL
43	NULL
.	NULL

Roman	NULL
C	NULL
,	NULL
Matera	NULL
G	NULL
,	NULL
Cooper	NULL
C	NULL
,	NULL
Artandi	NULL
S	NULL
,	NULL
Blain	NULL
S	NULL
,	NULL
Ward	NULL
D	NULL
,	NULL
Calame	NULL
K	NULL
:	NULL
mTFE3	NULL
,	NULL
an	NULL
X-linked	NULL
transcriptional	NULL
activator	NULL
containing	NULL
basic	NULL
helix-loop-helix	NULL
and	NULL
zipper	NULL
domains	NULL
,	NULL
utilizes	NULL
the	NULL
zipper	NULL
to	NULL
stabilize	NULL
both	NULL
DNA	NULL
binding	NULL
and	NULL
multimerization	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
12:817	NULL
,	NULL
1992	NULL
44	NULL
.	NULL

Lenardo	NULL
M	NULL
,	NULL
Pierce	NULL
JW	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Protein-binding	NULL
sites	NULL
in	NULL
Ig	NULL
gene	NULL
enhancers	NULL
determine	NULL
transcriptional	NULL
activity	NULL
and	NULL
inducibility	NULL
.	NULL

Science	NULL
236:1573	NULL
,	NULL
1987	NULL
45	NULL
.	NULL

Gregor	NULL
P	NULL
,	NULL
Sawadogo	NULL
M	NULL
,	NULL
Roeder	NULL
R	NULL
:	NULL
The	NULL
adenovirus	NULL
major	NULL
late	NULL
transcription	NULL
factor	NULL
USF	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
helix-loop-helix	NULL
group	NULL
of	NULL
regulatory	NULL
proteins	NULL
and	NULL
binds	NULL
to	NULL
DNA	NULL
as	NULL
a	NULL
dimer	NULL
.	NULL

Genes	NULL
Dev	NULL
4:1730	NULL
,	NULL
1990	NULL
46	NULL
.	NULL

Carr	NULL
C	NULL
,	NULL
Sharp	NULL
PA	NULL
:	NULL
A	NULL
helix-loop-helix	NULL
protein	NULL
related	NULL
to	NULL
the	NULL
immunoglobulin	NULL
E	NULL
box-binding	NULL
proteins	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
10:4384	NULL
,	NULL
1990	NULL
47	NULL
.	NULL

Chodosh	NULL
LA	NULL
,	NULL
Carthew	NULL
RW	NULL
,	NULL
Morgan	NULL
JG	NULL
,	NULL
Crabtree	NULL
GR	NULL
,	NULL
Sharp	NULL
PA	NULL
:	NULL
The	NULL
adenovirus	NULL
major	NULL
late	NULL
transcription	NULL
factor	NULL
activates	NULL
the	NULL
rat-y	NULL
fibrinogoen	NULL
promoter	NULL
.	NULL

Science	NULL
238:684	NULL
,	NULL
1987	NULL
48	NULL
.	NULL

Cogswell	NULL
JP	NULL
,	NULL
Godlevski	NULL
MM	NULL
,	NULL
Bonham	NULL
M	NULL
,	NULL
Bisi	NULL
J	NULL
,	NULL
Babiss	NULL
L	NULL
:	NULL
Upstream	NULL
stimulatory	NULL
factor	NULL
regulates	NULL
expression	NULL
of	NULL
the	NULL
cell	NULL
cycle-dependent	NULL
cyclin	NULL
B1	NULL
gene	NULL
promoter	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
15:2782	NULL
,	NULL
1995	NULL
49	NULL
.	NULL

Reisman	NULL
D	NULL
,	NULL
Rotter	NULL
V	NULL
:	NULL
The	NULL
helix-loop-helix	NULL
containing	NULL
transcription	NULL
factor	NULL
USF	NULL
binds	NULL
to	NULL
and	NULL
transactivates	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
p53	NULL
tumor	NULL
suppressor	NULL
gene	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
21:345	NULL
,	NULL
1993	NULL
50	NULL
.	NULL

Artandi	NULL
SE	NULL
,	NULL
Cooper	NULL
C	NULL
,	NULL
Shrivastava	NULL
A	NULL
,	NULL
Calame	NULL
K	NULL
:	NULL
The	NULL
basic	NULL
helix-loop-helix-zipper	NULL
domain	NULL
of	NULL
TFE3	NULL
mediates	NULL
enhancer-pro-moter	NULL
interaction	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
14:7704	NULL
,	NULL
1994	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Â®	NULL
blO	NULL
0d	NULL
1997	NULL
90	NULL
:	NULL
3984-3995	NULL
PU.1/Pip	NULL
and	NULL
Basic	NULL
Helix	NULL
Loop	NULL
Helix	NULL
Zipper	NULL
Transcription	NULL
Factors	NULL
Interact	NULL
With	NULL
Binding	NULL
Sites	NULL
in	NULL
the	NULL
CD20	NULL
Promoter	NULL
to	NULL
Help	NULL
Confer	NULL
Lineage-	NULL
and	NULL
Stage-Specific	NULL
Expression	NULL
of	NULL
CD20	NULL
in	NULL
B	NULL
Lymphocytes	NULL
A	NULL
_	NULL
48	NULL
o	NULL
6	NULL
'	NULL
t	NULL
\se	NULL
@	NULL
.	NULL

/	NULL
{	NULL
Â®	NULL
Andreas	NULL
Himmelmann	NULL
,	NULL
Agostino	NULL
Riva	NULL
,	NULL
Gaye	NULL
Lynn	NULL
Wilson	NULL
,	NULL
Brian	NULL
P.	NULL
Lucas	NULL
,	NULL
Claire	NULL
Thevenin	NULL
and	NULL
John	NULL
H.	NULL
Kehrl	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/90/10/3984.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Immunobiology	NULL
and	NULL
Immunotherapy	NULL
(	NULL
5674	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

